<!DOCTYPE html>
<html class='v2' dir='ltr'>
<head>
<meta content='width=1100' name='viewport'/>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type'/>
<script type="text/javascript">(function() { (function(){function c(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var h=a?new c(a.responseStart):new c;window.jstiming={Timer:c,load:h};if(a){var b=a.navigationStart,e=a.responseStart;0<b&&e>=b&&(window.jstiming.srt=e-b)}if(a){var d=window.jstiming.load;0<b&&e>=b&&(d.tick("_wtsrt",void 0,b),d.tick("wtsrt_",
"_wtsrt",e),d.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),d&&0<b&&(d.tick("_tbnd",void 0,window.chrome.csi().startE),d.tick("tbnd_","_tbnd",b))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,d&&0<b&&(d.tick("_tbnd",void 0,window.external.startE),d.tick("tbnd_","_tbnd",b))),a&&(window.jstiming.pt=a)}catch(k){}})();window.tickAboveFold=function(c){var a=0;if(c.offsetParent){do a+=c.offsetTop;while(c=c.offsetParent)}c=a;750>=c&&window.jstiming.load.tick("aft")};var f=!1;function g(){f||(f=!0,window.jstiming.load.tick("firstScrollTime"))}window.addEventListener?window.addEventListener("scroll",g,!1):window.attachEvent("onscroll",g);
 })();</script>
<meta content='blogger' name='generator'/>
<link href='http://innovip.blogspot.com/favicon.ico' rel='icon' type='image/x-icon'/>
<link href='http://innovip.blogspot.com/' rel='canonical'/>
<link rel="alternate" type="application/atom+xml" title="Random Thoughts: On R&amp;D, Innovation, IP and IT - Atom" href="http://innovip.blogspot.com/feeds/posts/default" />
<link rel="alternate" type="application/rss+xml" title="Random Thoughts: On R&amp;D, Innovation, IP and IT - RSS" href="http://innovip.blogspot.com/feeds/posts/default?alt=rss" />
<link rel="service.post" type="application/atom+xml" title="Random Thoughts: On R&amp;D, Innovation, IP and IT - Atom" href="https://www.blogger.com/feeds/4174420951068114981/posts/default" />
<link rel="me" href="https://www.blogger.com/profile/12006645854589278188" />
<link rel="openid.server" href="https://www.blogger.com/openid-server.g" />
<link rel="openid.delegate" href="http://innovip.blogspot.com/" />
<!--[if IE]><script type="text/javascript" src="https://www.blogger.com/static/v1/jsbin/1494333581-ieretrofit.js"></script>
<![endif]-->
<!--[if IE]> <script> (function() { var html5 = ("abbr,article,aside,audio,canvas,datalist,details," + "figure,footer,header,hgroup,mark,menu,meter,nav,output," + "progress,section,time,video").split(','); for (var i = 0; i < html5.length; i++) { document.createElement(html5[i]); } try { document.execCommand('BackgroundImageCache', false, true); } catch(e) {} })(); </script> <![endif]-->
<title>Random Thoughts: On R&amp;D, Innovation, IP and IT</title>
<script type="text/javascript">
WebFontConfig = {
  google: { families: [ 'Copse', 'Reenie Beanie' ],
  api: '//fonts.googleapis.com/css?kit=CSOZTlfx7RCNYtryOSYQytjk7Ppx9yfp2Wn3sZ2N5JM'
  },
  loading: function() {
    if (window.jstiming) window.jstiming.load.tick('webfontLoading');
  },
  active: function() {
    if (window.jstiming) window.jstiming.load.tick('webfontActive');
  }
};
(function() {
  var wf = document.createElement('script');
  wf.src = '//ajax.googleapis.com/ajax/libs/webfont/1/webfont.js';
  wf.type = 'text/javascript';
  wf.async = 'true';
  var s = document.getElementsByTagName('script')[0];
  s.parentNode.insertBefore(wf, s);
})();
</script>
<style type="text/css">
.wf-inactive .header h1, .wf-reeniebeanie-n4-loading .header h1, .wf-reeniebeanie-n4-inactive .header h1 {
  font-family: cursive;
}
.wf-inactive h3.post-title, .wf-copse-n4-loading h3.post-title, .wf-copse-n4-inactive h3.post-title, .wf-inactive .comments h4, .wf-copse-n4-loading .comments h4, .wf-copse-n4-inactive .comments h4 {
  font-family: serif;
}
</style>
<link type='text/css' rel='stylesheet' href='https://www.blogger.com/static/v1/widgets/2973171168-css_bundle_v2.css' />
<link type='text/css' rel='stylesheet' href='https://www.blogger.com/dyn-css/authorization.css?targetBlogID=4174420951068114981&zx=b6b8474f-4ff3-4791-bc6e-c4164e1a2d77' />
<style id='page-skin-1' type='text/css'><!--
/*
-----------------------------------------------
Blogger Template Style
Name:     Simple
Designer: Josh Peterson
URL:      www.noaesthetic.com
----------------------------------------------- */
/* Variable definitions
====================
<Variable name="keycolor" description="Main Color" type="color" default="#66bbdd"/>
<Group description="Page Text" selector="body">
<Variable name="body.font" description="Font" type="font"
default="normal normal 12px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/>
<Variable name="body.text.color" description="Text Color" type="color" default="#222222"/>
</Group>
<Group description="Backgrounds" selector=".body-fauxcolumns-outer">
<Variable name="body.background.color" description="Outer Background" type="color" default="#66bbdd"/>
<Variable name="content.background.color" description="Main Background" type="color" default="#ffffff"/>
<Variable name="header.background.color" description="Header Background" type="color" default="transparent"/>
</Group>
<Group description="Links" selector=".main-outer">
<Variable name="link.color" description="Link Color" type="color" default="#2288bb"/>
<Variable name="link.visited.color" description="Visited Color" type="color" default="#888888"/>
<Variable name="link.hover.color" description="Hover Color" type="color" default="#33aaff"/>
</Group>
<Group description="Blog Title" selector=".header h1">
<Variable name="header.font" description="Font" type="font"
default="normal normal 60px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/>
<Variable name="header.text.color" description="Title Color" type="color" default="#3399bb" />
</Group>
<Group description="Blog Description" selector=".header .description">
<Variable name="description.text.color" description="Description Color" type="color"
default="#777777" />
</Group>
<Group description="Tabs Text" selector=".tabs-inner .widget li a">
<Variable name="tabs.font" description="Font" type="font"
default="normal normal 14px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/>
<Variable name="tabs.text.color" description="Text Color" type="color" default="#999999"/>
<Variable name="tabs.selected.text.color" description="Selected Color" type="color" default="#000000"/>
</Group>
<Group description="Tabs Background" selector=".tabs-outer .PageList">
<Variable name="tabs.background.color" description="Background Color" type="color" default="#f5f5f5"/>
<Variable name="tabs.selected.background.color" description="Selected Color" type="color" default="#eeeeee"/>
</Group>
<Group description="Post Title" selector="h3.post-title, .comments h4">
<Variable name="post.title.font" description="Font" type="font"
default="normal normal 22px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/>
</Group>
<Group description="Date Header" selector=".date-header">
<Variable name="date.header.color" description="Text Color" type="color"
default="#222222"/>
<Variable name="date.header.background.color" description="Background Color" type="color"
default="transparent"/>
<Variable name="date.header.font" description="Text Font" type="font"
default="normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/>
<Variable name="date.header.padding" description="Date Header Padding" type="string" default="inherit"/>
<Variable name="date.header.letterspacing" description="Date Header Letter Spacing" type="string" default="inherit"/>
<Variable name="date.header.margin" description="Date Header Margin" type="string" default="inherit"/>
</Group>
<Group description="Post Footer" selector=".post-footer">
<Variable name="post.footer.text.color" description="Text Color" type="color" default="#666666"/>
<Variable name="post.footer.background.color" description="Background Color" type="color"
default="#f9f9f9"/>
<Variable name="post.footer.border.color" description="Shadow Color" type="color" default="#eeeeee"/>
</Group>
<Group description="Gadgets" selector="h2">
<Variable name="widget.title.font" description="Title Font" type="font"
default="normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif"/>
<Variable name="widget.title.text.color" description="Title Color" type="color" default="#000000"/>
<Variable name="widget.alternate.text.color" description="Alternate Color" type="color" default="#999999"/>
</Group>
<Group description="Images" selector=".main-inner">
<Variable name="image.background.color" description="Background Color" type="color" default="#ffffff"/>
<Variable name="image.border.color" description="Border Color" type="color" default="#eeeeee"/>
<Variable name="image.text.color" description="Caption Text Color" type="color" default="#222222"/>
</Group>
<Group description="Accents" selector=".content-inner">
<Variable name="body.rule.color" description="Separator Line Color" type="color" default="#eeeeee"/>
<Variable name="tabs.border.color" description="Tabs Border Color" type="color" default="#eeeeee"/>
</Group>
<Variable name="body.background" description="Body Background" type="background"
color="#66bbdd" default="$(color) none repeat scroll top left"/>
<Variable name="body.background.override" description="Body Background Override" type="string" default=""/>
<Variable name="body.background.gradient.cap" description="Body Gradient Cap" type="url"
default="url(//www.blogblog.com/1kt/simple/gradients_light.png)"/>
<Variable name="body.background.gradient.tile" description="Body Gradient Tile" type="url"
default="url(//www.blogblog.com/1kt/simple/body_gradient_tile_light.png)"/>
<Variable name="content.background.color.selector" description="Content Background Color Selector" type="string" default=".content-inner"/>
<Variable name="content.padding" description="Content Padding" type="length" default="10px" min="0" max="100px"/>
<Variable name="content.padding.horizontal" description="Content Horizontal Padding" type="length" default="10px" min="0" max="100px"/>
<Variable name="content.shadow.spread" description="Content Shadow Spread" type="length" default="40px" min="0" max="100px"/>
<Variable name="content.shadow.spread.webkit" description="Content Shadow Spread (WebKit)" type="length" default="5px" min="0" max="100px"/>
<Variable name="content.shadow.spread.ie" description="Content Shadow Spread (IE)" type="length" default="10px" min="0" max="100px"/>
<Variable name="main.border.width" description="Main Border Width" type="length" default="0" min="0" max="10px"/>
<Variable name="header.background.gradient" description="Header Gradient" type="url" default="none"/>
<Variable name="header.shadow.offset.left" description="Header Shadow Offset Left" type="length" default="-1px" min="-50px" max="50px"/>
<Variable name="header.shadow.offset.top" description="Header Shadow Offset Top" type="length" default="-1px" min="-50px" max="50px"/>
<Variable name="header.shadow.spread" description="Header Shadow Spread" type="length" default="1px" min="0" max="100px"/>
<Variable name="header.padding" description="Header Padding" type="length" default="30px" min="0" max="100px"/>
<Variable name="header.border.size" description="Header Border Size" type="length" default="1px" min="0" max="10px"/>
<Variable name="header.bottom.border.size" description="Header Bottom Border Size" type="length" default="1px" min="0" max="10px"/>
<Variable name="header.border.horizontalsize" description="Header Horizontal Border Size" type="length" default="0" min="0" max="10px"/>
<Variable name="description.text.size" description="Description Text Size" type="string" default="140%"/>
<Variable name="tabs.margin.top" description="Tabs Margin Top" type="length" default="0" min="0" max="100px"/>
<Variable name="tabs.margin.side" description="Tabs Side Margin" type="length" default="30px" min="0" max="100px"/>
<Variable name="tabs.background.gradient" description="Tabs Background Gradient" type="url"
default="url(//www.blogblog.com/1kt/simple/gradients_light.png)"/>
<Variable name="tabs.border.width" description="Tabs Border Width" type="length" default="1px" min="0" max="10px"/>
<Variable name="tabs.bevel.border.width" description="Tabs Bevel Border Width" type="length" default="1px" min="0" max="10px"/>
<Variable name="post.margin.bottom" description="Post Bottom Margin" type="length" default="25px" min="0" max="100px"/>
<Variable name="image.border.small.size" description="Image Border Small Size" type="length" default="2px" min="0" max="10px"/>
<Variable name="image.border.large.size" description="Image Border Large Size" type="length" default="5px" min="0" max="10px"/>
<Variable name="page.width.selector" description="Page Width Selector" type="string" default=".region-inner"/>
<Variable name="page.width" description="Page Width" type="string" default="auto"/>
<Variable name="main.section.margin" description="Main Section Margin" type="length" default="15px" min="0" max="100px"/>
<Variable name="main.padding" description="Main Padding" type="length" default="15px" min="0" max="100px"/>
<Variable name="main.padding.top" description="Main Padding Top" type="length" default="30px" min="0" max="100px"/>
<Variable name="main.padding.bottom" description="Main Padding Bottom" type="length" default="30px" min="0" max="100px"/>
<Variable name="paging.background"
color="#ffffff"
description="Background of blog paging area" type="background"
default="transparent none no-repeat scroll top center"/>
<Variable name="footer.bevel" description="Bevel border length of footer" type="length" default="0" min="0" max="10px"/>
<Variable name="mobile.background.overlay" description="Mobile Background Overlay" type="string"
default="transparent none repeat scroll top left"/>
<Variable name="mobile.background.size" description="Mobile Background Size" type="string" default="auto"/>
<Variable name="mobile.button.color" description="Mobile Button Color" type="color" default="#ffffff" />
<Variable name="startSide" description="Side where text starts in blog language" type="automatic" default="left"/>
<Variable name="endSide" description="Side where text ends in blog language" type="automatic" default="right"/>
*/
/* Content
----------------------------------------------- */
body {
font: normal normal 12px Arial, Tahoma, Helvetica, FreeSans, sans-serif;
color: #222222;
background: #66bbdd none repeat scroll top left;
padding: 0 40px 40px 40px;
}
html body .region-inner {
min-width: 0;
max-width: 100%;
width: auto;
}
h2 {
font-size: 22px;
}
a:link {
text-decoration:none;
color: #2288bb;
}
a:visited {
text-decoration:none;
color: #888888;
}
a:hover {
text-decoration:underline;
color: #33aaff;
}
.body-fauxcolumn-outer .fauxcolumn-inner {
background: transparent url(//www.blogblog.com/1kt/simple/body_gradient_tile_light.png) repeat scroll top left;
_background-image: none;
}
.body-fauxcolumn-outer .cap-top {
position: absolute;
z-index: 1;
height: 400px;
width: 100%;
background: #66bbdd none repeat scroll top left;
}
.body-fauxcolumn-outer .cap-top .cap-left {
width: 100%;
background: transparent url(//www.blogblog.com/1kt/simple/gradients_light.png) repeat-x scroll top left;
_background-image: none;
}
.content-outer {
-moz-box-shadow: 0 0 40px rgba(0, 0, 0, .15);
-webkit-box-shadow: 0 0 5px rgba(0, 0, 0, .15);
-goog-ms-box-shadow: 0 0 10px #333333;
box-shadow: 0 0 40px rgba(0, 0, 0, .15);
margin-bottom: 1px;
}
.content-inner {
padding: 10px 10px;
}
.content-inner {
background-color: #ffffff;
}
/* Header
----------------------------------------------- */
.header-outer {
background: transparent none repeat-x scroll 0 -400px;
_background-image: none;
}
.Header h1 {
font: normal bold 42px Reenie Beanie;
color: #5690c3;
text-shadow: -1px -1px 1px rgba(0, 0, 0, .2);
}
.Header h1 a {
color: #5690c3;
}
.Header .description {
font-size: 140%;
color: #222222;
}
.header-inner .Header .titlewrapper {
padding: 22px 30px;
}
.header-inner .Header .descriptionwrapper {
padding: 0 30px;
}
/* Tabs
----------------------------------------------- */
.tabs-inner .section:first-child {
border-top: 1px solid #eeeeee;
}
.tabs-inner .section:first-child ul {
margin-top: -1px;
border-top: 1px solid #eeeeee;
border-left: 0 solid #eeeeee;
border-right: 0 solid #eeeeee;
}
.tabs-inner .widget ul {
background: #ffffff url(//www.blogblog.com/1kt/simple/gradients_light.png) repeat-x scroll 0 -800px;
_background-image: none;
border-bottom: 1px solid #eeeeee;
margin-top: 0;
margin-left: -30px;
margin-right: -30px;
}
.tabs-inner .widget li a {
display: inline-block;
padding: .6em 1em;
font: normal normal 14px Arial, Tahoma, Helvetica, FreeSans, sans-serif;
color: #ffffff;
border-left: 1px solid #ffffff;
border-right: 1px solid #eeeeee;
}
.tabs-inner .widget li:first-child a {
border-left: none;
}
.tabs-inner .widget li.selected a, .tabs-inner .widget li a:hover {
color: #000000;
background-color: #eeeeee;
text-decoration: none;
}
/* Columns
----------------------------------------------- */
.main-outer {
border-top: 0 solid #eeeeee;
}
.fauxcolumn-left-outer .fauxcolumn-inner {
border-right: 1px solid #eeeeee;
}
.fauxcolumn-right-outer .fauxcolumn-inner {
border-left: 1px solid #eeeeee;
}
/* Headings
----------------------------------------------- */
div.widget > h2,
div.widget h2.title {
margin: 0 0 1em 0;
font: normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif;
color: #000000;
}
/* Widgets
----------------------------------------------- */
.widget .zippy {
color: #999999;
text-shadow: 2px 2px 1px rgba(0, 0, 0, .1);
}
.widget .popular-posts ul {
list-style: none;
}
/* Posts
----------------------------------------------- */
h2.date-header {
font: normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif;
}
.date-header span {
background-color: transparent;
color: #222222;
padding: inherit;
letter-spacing: inherit;
margin: inherit;
}
.main-inner {
padding-top: 30px;
padding-bottom: 30px;
}
.main-inner .column-center-inner {
padding: 0 15px;
}
.main-inner .column-center-inner .section {
margin: 0 15px;
}
.post {
margin: 0 0 25px 0;
}
h3.post-title, .comments h4 {
font: normal bold 30px Copse;
margin: .75em 0 0;
}
.post-body {
font-size: 110%;
line-height: 1.4;
position: relative;
}
.post-body img, .post-body .tr-caption-container, .Profile img, .Image img,
.BlogList .item-thumbnail img {
padding: 2px;
background: #ffffff;
border: 1px solid #eeeeee;
-moz-box-shadow: 1px 1px 5px rgba(0, 0, 0, .1);
-webkit-box-shadow: 1px 1px 5px rgba(0, 0, 0, .1);
box-shadow: 1px 1px 5px rgba(0, 0, 0, .1);
}
.post-body img, .post-body .tr-caption-container {
padding: 5px;
}
.post-body .tr-caption-container {
color: #222222;
}
.post-body .tr-caption-container img {
padding: 0;
background: transparent;
border: none;
-moz-box-shadow: 0 0 0 rgba(0, 0, 0, .1);
-webkit-box-shadow: 0 0 0 rgba(0, 0, 0, .1);
box-shadow: 0 0 0 rgba(0, 0, 0, .1);
}
.post-header {
margin: 0 0 1.5em;
line-height: 1.6;
font-size: 90%;
}
.post-footer {
margin: 20px -2px 0;
padding: 5px 10px;
color: #666666;
background-color: #f9f9f9;
border-bottom: 1px solid #eeeeee;
line-height: 1.6;
font-size: 90%;
}
#comments .comment-author {
padding-top: 1.5em;
border-top: 1px solid #eeeeee;
background-position: 0 1.5em;
}
#comments .comment-author:first-child {
padding-top: 0;
border-top: none;
}
.avatar-image-container {
margin: .2em 0 0;
}
#comments .avatar-image-container img {
border: 1px solid #eeeeee;
}
/* Comments
----------------------------------------------- */
.comments .comments-content .icon.blog-author {
background-repeat: no-repeat;
background-image: url(data:image/png;base64,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);
}
.comments .comments-content .loadmore a {
border-top: 1px solid #999999;
border-bottom: 1px solid #999999;
}
.comments .comment-thread.inline-thread {
background-color: #f9f9f9;
}
.comments .continue {
border-top: 2px solid #999999;
}
/* Accents
---------------------------------------------- */
.section-columns td.columns-cell {
border-left: 1px solid #eeeeee;
}
.blog-pager {
background: transparent none no-repeat scroll top center;
}
.blog-pager-older-link, .home-link,
.blog-pager-newer-link {
background-color: #ffffff;
padding: 5px;
}
.footer-outer {
border-top: 0 dashed #bbbbbb;
}
/* Mobile
----------------------------------------------- */
body.mobile  {
background-size: auto;
}
.mobile .body-fauxcolumn-outer {
background: transparent none repeat scroll top left;
}
.mobile .body-fauxcolumn-outer .cap-top {
background-size: 100% auto;
}
.mobile .content-outer {
-webkit-box-shadow: 0 0 3px rgba(0, 0, 0, .15);
box-shadow: 0 0 3px rgba(0, 0, 0, .15);
}
.mobile .tabs-inner .widget ul {
margin-left: 0;
margin-right: 0;
}
.mobile .post {
margin: 0;
}
.mobile .main-inner .column-center-inner .section {
margin: 0;
}
.mobile .date-header span {
padding: 0.1em 10px;
margin: 0 -10px;
}
.mobile h3.post-title {
margin: 0;
}
.mobile .blog-pager {
background: transparent none no-repeat scroll top center;
}
.mobile .footer-outer {
border-top: none;
}
.mobile .main-inner, .mobile .footer-inner {
background-color: #ffffff;
}
.mobile-index-contents {
color: #222222;
}
.mobile-link-button {
background-color: #2288bb;
}
.mobile-link-button a:link, .mobile-link-button a:visited {
color: #ffffff;
}
.mobile .tabs-inner .section:first-child {
border-top: none;
}
.mobile .tabs-inner .PageList .widget-content {
background-color: #eeeeee;
color: #000000;
border-top: 1px solid #eeeeee;
border-bottom: 1px solid #eeeeee;
}
.mobile .tabs-inner .PageList .widget-content .pagelist-arrow {
border-left: 1px solid #eeeeee;
}

--></style>
<style id='template-skin-1' type='text/css'><!--
body {
min-width: 1160px;
}
.content-outer, .content-fauxcolumn-outer, .region-inner {
min-width: 1160px;
max-width: 1160px;
_width: 1160px;
}
.main-inner .columns {
padding-left: 0;
padding-right: 290px;
}
.main-inner .fauxcolumn-center-outer {
left: 0;
right: 290px;
/* IE6 does not respect left and right together */
_width: expression(this.parentNode.offsetWidth -
parseInt("0") -
parseInt("290px") + 'px');
}
.main-inner .fauxcolumn-left-outer {
width: 0;
}
.main-inner .fauxcolumn-right-outer {
width: 290px;
}
.main-inner .column-left-outer {
width: 0;
right: 100%;
margin-left: -0;
}
.main-inner .column-right-outer {
width: 290px;
margin-right: -290px;
}
#layout {
min-width: 0;
}
#layout .content-outer {
min-width: 0;
width: 800px;
}
#layout .region-inner {
min-width: 0;
width: auto;
}
--></style>
<script type="text/javascript">var a="&m=1",d="(^|&)m=",e="?",f="?m=1";function g(){var b=window.location.href,c=b.split(e);switch(c.length){case 1:return b+f;case 2:return 0<=c[1].search(d)?null:b+a;default:return null}}var h=navigator.userAgent;if(-1!=h.indexOf("Mobile")&&-1!=h.indexOf("WebKit")&&-1==h.indexOf("iPad")||-1!=h.indexOf("Opera Mini")||-1!=h.indexOf("IEMobile")){var k=g();k&&window.location.replace(k)};
</script><script type="text/javascript">
if (window.jstiming) window.jstiming.load.tick('headEnd');
</script></head>
<body class='loading variant-pale'>
<div class='navbar section' id='navbar' name='Navbar'><div class='widget Navbar' id='Navbar1'><script type="text/javascript">
    function setAttributeOnload(object, attribute, val) {
      if(window.addEventListener) {
        window.addEventListener('load',
          function(){ object[attribute] = val; }, false);
      } else {
        window.attachEvent('onload', function(){ object[attribute] = val; });
      }
    }
  </script>
<div id="navbar-iframe-container"></div>
<script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script>
<script type="text/javascript">
        gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() {
          if (gapi.iframes && gapi.iframes.getContext) {
            gapi.iframes.getContext().openChild({
                url: 'https://www.blogger.com/navbar.g?targetBlogID\0754174420951068114981\46blogName\75Random+Thoughts:+On+R%26D,+Innovation,+...\46publishMode\75PUBLISH_MODE_BLOGSPOT\46navbarType\75LIGHT\46layoutType\75LAYOUTS\46searchRoot\75//innovip.blogspot.com/search\46blogLocale\75en\46v\0752\46homepageUrl\75http://innovip.blogspot.com/\46vt\75-9018875939593677227',
                where: document.getElementById("navbar-iframe-container"),
                id: "navbar-iframe"
            });
          }
        });
      </script><script type="text/javascript">
(function() {
var script = document.createElement('script');
script.type = 'text/javascript';
script.src = '//pagead2.googlesyndication.com/pagead/js/google_top_exp.js';
var head = document.getElementsByTagName('head')[0];
if (head) {
head.appendChild(script);
}})();
</script>
</div></div>
<div itemscope='itemscope' itemtype='http://schema.org/Blog' style='display: none;'>
<meta content='Random Thoughts: On R&amp;D, Innovation, IP and IT' itemprop='name'/>
</div>
<div class='body-fauxcolumns'>
<div class='fauxcolumn-outer body-fauxcolumn-outer'>
<div class='cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left'>
<div class='fauxborder-right'></div>
<div class='fauxcolumn-inner'>
</div>
</div>
<div class='cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
</div>
<div class='content'>
<div class='content-fauxcolumns'>
<div class='fauxcolumn-outer content-fauxcolumn-outer'>
<div class='cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left'>
<div class='fauxborder-right'></div>
<div class='fauxcolumn-inner'>
</div>
</div>
<div class='cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
</div>
<div class='content-outer'>
<div class='content-cap-top cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left content-fauxborder-left'>
<div class='fauxborder-right content-fauxborder-right'></div>
<div class='content-inner'>
<header>
<div class='header-outer'>
<div class='header-cap-top cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left header-fauxborder-left'>
<div class='fauxborder-right header-fauxborder-right'></div>
<div class='region-inner header-inner'>
<div class='header section' id='header' name='Header'><div class='widget Header' id='Header1'>
<div id='header-inner'>
<div class='titlewrapper'>
<h1 class='title'>
Random Thoughts: On R&amp;D, Innovation, IP and IT
</h1>
</div>
<div class='descriptionwrapper'>
<p class='description'><span>Zakir Thomas' Blog</span></p>
</div>
</div>
</div></div>
</div>
</div>
<div class='header-cap-bottom cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
</header>
<div class='tabs-outer'>
<div class='tabs-cap-top cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left tabs-fauxborder-left'>
<div class='fauxborder-right tabs-fauxborder-right'></div>
<div class='region-inner tabs-inner'>
<div class='tabs section' id='crosscol' name='Cross-Column'></div>
<div class='tabs section' id='crosscol-overflow' name='Cross-Column 2'></div>
</div>
</div>
<div class='tabs-cap-bottom cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
<div class='main-outer'>
<div class='main-cap-top cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left main-fauxborder-left'>
<div class='fauxborder-right main-fauxborder-right'></div>
<div class='region-inner main-inner'>
<div class='columns fauxcolumns'>
<div class='fauxcolumn-outer fauxcolumn-center-outer'>
<div class='cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left'>
<div class='fauxborder-right'></div>
<div class='fauxcolumn-inner'>
</div>
</div>
<div class='cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
<div class='fauxcolumn-outer fauxcolumn-left-outer'>
<div class='cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left'>
<div class='fauxborder-right'></div>
<div class='fauxcolumn-inner'>
</div>
</div>
<div class='cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
<div class='fauxcolumn-outer fauxcolumn-right-outer'>
<div class='cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left'>
<div class='fauxborder-right'></div>
<div class='fauxcolumn-inner'>
</div>
</div>
<div class='cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
<!-- corrects IE6 width calculation -->
<div class='columns-inner'>
<div class='column-center-outer'>
<div class='column-center-inner'>
<div class='main section' id='main' name='Main'><div class='widget Blog' id='Blog1'>
<div class='blog-posts hfeed'>

          <div class="date-outer">
        
<h2 class='date-header'><span>Sunday, August 30, 2015</span></h2>

          <div class="date-posts">
        
<div class='post-outer'>
<div class='post hentry uncustomized-post-template' itemprop='blogPost' itemscope='itemscope' itemtype='http://schema.org/BlogPosting'>
<meta content='4174420951068114981' itemprop='blogId'/>
<meta content='6558549916664767302' itemprop='postId'/>
<a name='6558549916664767302'></a>
<h3 class='post-title entry-title' itemprop='name'>
<a href='http://innovip.blogspot.com/2015/08/why-are-r-centers-closing-down.html'>Why are Indian R&D Centers Closing Down?</a>
</h3>
<div class='post-header'>
<div class='post-header-line-1'></div>
</div>
<div class='post-body entry-content' id='post-body-6558549916664767302' itemprop='description articleBody'>
<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">Are the top tier private R&amp;D organisations in India closing
down their operations? Just look at the following data compiled by <a href="http://www.biospectrumasia.com/biospectrum/news/222247/merck-confirms-shutting-bangalore-genei-facility/page/3" target="_blank">Biospectrum in its August 2015 issue</a></span><span style="font-family: Symbol; font-size: 14pt; line-height: 107%; text-align: left; text-indent: -0.25in;"><span style="font-family: 'Times New Roman'; font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;</span></span></div>
<div class="MsoNormal" style="text-align: justify;">
</div>
<ul>
<li><span style="font-size: 14pt; line-height: 107%; text-align: left; text-indent: -0.25in;">In
January 2014, AstraZeneca announced the shutting down of its drug R&amp;D unit,
dedicated for neglected diseases, one of its kind, located in Bangalore.</span><span style="font-family: Symbol; font-size: 14pt; line-height: 107%; text-indent: -0.25in;"><span style="font-family: 'Times New Roman'; font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;</span></span></li>
<li><span style="font-size: 14pt; line-height: 107%; text-indent: -0.25in;">In
August 2014, Indian healthcare giant Piramal announced its decision to shut its
Mumbai R&amp;D unit.</span></li>
<li><span style="font-size: 14pt; line-height: 107%; text-indent: -0.25in;">In
2015 Pfizer's Thane plant is shutting down its operations.</span></li>
<li><span style="font-size: 14pt; line-height: 107%; text-indent: -0.25in;">Sandoz
is shutting down its Turbhe R&amp;D site in Maharashtra</span></li>
<li><span style="font-size: 14pt; line-height: 107%; text-indent: -0.25in;">Merck has announced shutting down of its Bangalore Genei
facility, recently.</span></li>
</ul>
<span style="font-size: 18.6666660308838px; line-height: 19.973331451416px; text-align: justify;">Those who are familiar with the South Indian way of speaking English would have heard this expression &#8211; "what is happening, I say?!" (in typical south Indian fashion, &#8216;say&#8217; pronounced with an elongation). That&#8217;s the question that comes to one&#8217;s mind as R&amp;D centers shut down one by one.&nbsp;</span><br />
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14pt; line-height: 107%;">To set the record straight, Pfizer&#8217;s Thane plant was a
manufacturing facility. Same is the case with Sandoz Thurbe plant which was
manufacturing APIs. Others are all R&amp;D units. This does not digress from the fact of R&amp;D closures - Biospectrum has brought out
an important issue.&nbsp;</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14pt; line-height: 107%;">It is tempting to see these closing downs as random business
operation and go on with business as usual. The numbers are far too
many to lose sight of its significance. The R&amp;D units that are being shut
down are in pharmaceutical sector, a key driver of innovation. In
pharmaceutical sector, it is R&amp;D which determines the standing in the
pecking order. As I discuss below, it might have&nbsp;</span><span style="font-size: 18.6666660308838px; line-height: 19.973331451416px;">repercussions</span><span style="font-size: 14pt; line-height: 107%;">&nbsp;in other areas.&nbsp;<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">Way back in 2004, noted columnist Swaminathan S.
Anklesaria Aiyar (<a href="http://swaminomics.org/" target="_blank">Swaminomics</a>), in his column in The Times of India, titled &#8216;<a href="http://swaminomics.org/rd-indias-new-star-industry/" target="_blank">R&amp;D: India&#8217;s New Star Industry</a>&#8217;, had pointed out the emergence of R&amp;D industry in India. During the license permit raj there was no incentive to do R&amp;D, he argued. The
competition brought in by economic liberalisation in the 1990s made R&amp;D is
an essential tool to compete and survive. He warned the Americans who complain
about call centers that they had not seen anything yet, as biggest American
companies were setting up R&amp;D centers in India; citing examples of setting
up of R&amp;D centers by General Electric, Microsoft, IBM, Cisco, Intel,
General Motors, Astra Zeneca, Motorola , Texas Instruments. He
predicted an R&amp;D revolution in India and hoped with many other Indians for blooming
of Indian R&amp;D. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">A decade later, it looks like <a href="http://swaminomics.org/rd-indias-new-star-industry/" target="_blank">Swaminomics</a> has had to eat his words. Instead of bloom, we are witnessing a withering; we are witnessing a
slow retreat by those who set up their R&amp;D centers. And at the same time, some of Indian R&amp;D companies are going abroad to set up their research facilities. <a href="http://www.glenmarkpharma.com/UITemplate/HtmlContainer.aspx?res=P_GLN_GDY_PRND_PSWZ" target="_blank">Glenmark has set up an R&amp;D center in Switzerland</a>. This is a reason for
worry about anyone who is interested in R&amp;D and innovation in India. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">In India, prior to the wave of MNC R&amp;D centers cited
above by Swaminathan S. Anklesaria Aiyar, R&amp;D was done mainly in the public
sector laboratories. The <a href="https://en.wikipedia.org/wiki/National_Metallurgical_Laboratory" target="_blank">traditional Indian public policy approach on R&amp;D</a>
was to create a golden handshake of public sector laboratories and private
enterprises. Public sector labs were established to support R&amp;D in the
industry. In 1944, the then Government released &#8377;10 million (US$150,966) to set up
National Physical Laboratory, National Chemical Laboratory and National
Metallurgical Laboratory (NML). The stated objective was to develop industry in
pre-independent India, and also to incentivize private firms to support
industrial research. It worked; the objective was met. The Tata Trust promised
to donate &#8377;1.17 million (US$18,000) to NML. &nbsp;The government in its turn located NML at Jamshedpur,
where Tata Steel is located. For many decades, and even now, NML provide world
class R&amp;D support to Tata Steel located at Jamshedpur.
Two other laboratories <a href="http://www.cimfr.nic.in/prof.html" target="_blank">Central Mining Research Institute(CMRI) &nbsp;and Central Fuel Research Institute (CFRI)</a>,
were set up to provide basic research, R &amp; D back up, advisory services and
help in technology upgradation and adaptation to coal and mineral based
industries to reach the targeted production with high standards of safety,
economy and cleaner environment. These two labs were later merged to create Central Institute of Mining and Fuel
Research (<a href="http://www.cimfr.nic.in/prof.html" target="_blank">CSIR-CIMFR</a>). CSIR&#8217;s chemical laboratories have been the backbone of India&#8217;s
generic industry and it has been <a href="http://www.nature.com/news/india-the-fight-to-become-a-science-superpower-1.17518" target="_blank">acknowledged widely</a>.&nbsp;<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">The setting up of private sector R&amp;D by MNC majors as
pointed out by Swaminathan Ankaleseria Ayer was a qualitative shift, which
acknowledged the research capability available in the country which could give
competitive advantage to MNCs, globally. He wrote: &#8220;The biggest American
companies are now setting up R&amp;D centres in India. They are not coming for
cheap labour in sweatshops. They are coming for India&#8217;s brains.&#8221; Indian
education system had produced quality human resources who could produce world
class R&amp;D for MNCs. From a public sector dominated R&amp;D, India was
moving to private sector R&amp;D, which, it was hoped would drive innovation
and growth. This shift is getting reversed with dangerous portents.&nbsp;<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">Those who are familiar with R&amp;D and innovation knows very
well that both innovation and R&amp;D thrives within the surrounding ecosystem. The early
movers into R&amp;D centers have therefore taken extra pains to set up the
ecosystem around them. For example, the Astra Zeneca research center at
Bangalore created a drug discovery ecosystem around it. It was benefited by the
scientific innovation ecosystem created by the Indian Institute of Science.
This ecosystem enabled creation of Contract Research Organisations who do
contract R&amp;D for global majors. Shutting down of the research centers decimates
the ecosystem that got developed. Repeated shutting down as Biospectrum has
pointed out might irreversibly damage the ecosystem built up assiduously, with
great effort.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">How challenging is it to set up a new R&amp;D center in
India? If experience of some passionate ex scientists of Astra Zeneca is
anything to go by, it is an uphill task, choked by bureaucratic stranglehold. Dr
R K Shandil, Dr Sridhar Narayanan were with Astra Zeneca facility which was
shut down. Passionate about discovering new drugs for neglected diseases, they
founded a <a href="http://fndr.in/" target="_blank">Foundation for Neglected Diseases Research</a>, along with P Gopal
Krishnan, a Chartered Accountant. After almost a year of its setting up, they
are still running from pillar to post to get the approvals required to set up an
R&amp;D unit, a drug research facility for tropical infectious diseases which
predominantly affect India. Will we ever learn to make it easy for people to do
business, even if our Prime Minister himself wants it? Luckily scientists are
optimists and they are still at it. But when decisions are taken on business
considerations by MNCs, luck plays very limited role.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">The Prime Minister of India gives considerable importance to developing
manufacturing facilities in India which will create jobs, through his 'Make in
India' campaign. Make in India requires extensive R&amp;D. The shutting down of
R&amp;D centers does not augur well for the make in India campaign. Policy
makers need to realise this.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">The much acclaimed human resources (&#8216;brain power&#8217; and
research capability) still exists in the country. Indian minds are driving
innovation in many parts of the world. Then, why are these R&amp;D centers are
shutting down? The reasons have to be systemic, and goes far beyond the
availability of skilled human resources. These reasons are definitely large enough to obfuscate the human resource and cost advantage that India
enjoys. Our policy makers need to find the real reasons and take quick corrective measures.<o:p></o:p></span></div>
<br />
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
</div>
<div style='clear: both;'></div>
</div>
<div class='post-footer'>
<div class='post-footer-line post-footer-line-1'>
<span class='post-author vcard'>
Posted by
<span class='fn' itemprop='author' itemscope='itemscope' itemtype='http://schema.org/Person'>
<meta content='https://www.blogger.com/profile/12006645854589278188' itemprop='url'/>
<a class='g-profile' href='https://www.blogger.com/profile/12006645854589278188' rel='author' title='author profile'>
<span itemprop='name'>Zakir Thomas</span>
</a>
</span>
</span>
<span class='post-timestamp'>
at
<meta content='http://innovip.blogspot.com/2015/08/why-are-r-centers-closing-down.html' itemprop='url'/>
<a class='timestamp-link' href='http://innovip.blogspot.com/2015/08/why-are-r-centers-closing-down.html' rel='bookmark' title='permanent link'><abbr class='published' itemprop='datePublished' title='2015-08-30T01:53:00-07:00'>1:53 AM</abbr></a>
</span>
<span class='reaction-buttons'>
</span>
<span class='post-comment-link'>
<a class='comment-link' href='http://innovip.blogspot.com/2015/08/why-are-r-centers-closing-down.html#comment-form' onclick=''>
No comments:
    </a>
</span>
<span class='post-backlinks post-comment-link'>
</span>
<span class='post-icons'>
<span class='item-control blog-admin pid-946377361'>
<a href='https://www.blogger.com/post-edit.g?blogID=4174420951068114981&postID=6558549916664767302&from=pencil' title='Edit Post'>
<img alt='' class='icon-action' height='18' src='//img2.blogblog.com/img/icon18_edit_allbkg.gif' width='18'/>
</a>
</span>
</span>
<div class='post-share-buttons goog-inline-block'>
<a class='goog-inline-block share-button sb-email' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=6558549916664767302&target=email' target='_blank' title='Email This'><span class='share-button-link-text'>Email This</span></a><a class='goog-inline-block share-button sb-blog' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=6558549916664767302&target=blog' onclick='window.open(this.href, "_blank", "height=270,width=475"); return false;' target='_blank' title='BlogThis!'><span class='share-button-link-text'>BlogThis!</span></a><a class='goog-inline-block share-button sb-twitter' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=6558549916664767302&target=twitter' target='_blank' title='Share to Twitter'><span class='share-button-link-text'>Share to Twitter</span></a><a class='goog-inline-block share-button sb-facebook' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=6558549916664767302&target=facebook' onclick='window.open(this.href, "_blank", "height=430,width=640"); return false;' target='_blank' title='Share to Facebook'><span class='share-button-link-text'>Share to Facebook</span></a><a class='goog-inline-block share-button sb-pinterest' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=6558549916664767302&target=pinterest' target='_blank' title='Share to Pinterest'><span class='share-button-link-text'>Share to Pinterest</span></a><div class='goog-inline-block google-plus-share-container'><g:plusone source='blogger:blog:plusone' href='http://innovip.blogspot.com/2015/08/why-are-r-centers-closing-down.html' size='medium' width='300' annotation='inline'/></div>
</div>
</div>
<div class='post-footer-line post-footer-line-2'>
<span class='post-labels'>
</span>
</div>
<div class='post-footer-line post-footer-line-3'>
<span class='post-location'>
</span>
</div>
</div>
</div>
</div>

          </div></div>
        

          <div class="date-outer">
        
<h2 class='date-header'><span>Thursday, August 13, 2015</span></h2>

          <div class="date-posts">
        
<div class='post-outer'>
<div class='post hentry uncustomized-post-template' itemprop='blogPost' itemscope='itemscope' itemtype='http://schema.org/BlogPosting'>
<meta content='4174420951068114981' itemprop='blogId'/>
<meta content='4036545927943992773' itemprop='postId'/>
<a name='4036545927943992773'></a>
<h3 class='post-title entry-title' itemprop='name'>
<a href='http://innovip.blogspot.com/2015/08/the-economist-decries-patent-system.html'>The Economist Decries Patent System</a>
</h3>
<div class='post-header'>
<div class='post-header-line-1'></div>
</div>
<div class='post-body entry-content' id='post-body-4036545927943992773' itemprop='description articleBody'>
<div dir="ltr" style="text-align: left;" trbidi="on">
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">The Economist, one of the most reputed journals, has raised a red flag on the patent system, with a
cover story titled &#8216;<a href="http://www.economist.com/news/leaders/21660522-ideas-fuel-economy-todays-patent-systems-are-rotten-way-rewarding-them-time-fix" target="_blank">Set Innovation Free: Time to Fix the Patent System</a>&#8217; in its
August 8<sup>th</sup> to 14<sup>th</sup>, 2015 issue. Its Editorial titled &#8216;Innovation:
Time to Fix Patents&#8217; states: "</span><span style="font-size: 14pt; line-height: 107%; text-align: left;">Today&#8217;s patent regime operates in the
name of progress. Instead it sets innovation back. Time to fix it."</span><br />
<span style="font-size: 14pt; line-height: 107%; text-align: left;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">The issue carries an Editorial (called leader in The Economist
parlance) and a detailed 3 page article titled &#8216;Intellectual Property: A
Question of Utility&#8217;. The main arguments put forward against the patent system
is summarized below:<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">i.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">Evidence
show that stronger patent system do not necessarily promote innovation. In a
surprising twist to the narrative, more akin to the lingua of a civil society
organization, The Economist goes back to the history and recall that the
industrial revolution that led to steam ships to the railroads did not have
patents as we know today. &nbsp;It also recall
that it argued against patents in the 19<sup>th</sup> century. <o:p></o:p></span><br />
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">ii.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
policy premise supporting patents is they serve public good. It provides an
incentive to innovate and publish the new idea, in return of a material gain.
Publication of new ideas spread the technological advancement as one innovation
builds on another. The Economist argues that the evidence to support this claim
is weak. Patent documents are carefully written by experts to obscure how it
works even from the experts in the field. Instead of spreading knowledge, the
current patent system has created a parasitic ecology of trolls and defensive
patent holders, who aim to block innovation to grab a share of the spoils than
to promote innovation.<o:p></o:p></span><br />
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">iii.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">A
growing body of research including a 2004 study by the National Academy of
Sciences led to the conclusion that the society as a whole might be better off
with no patents, with a few exceptions, such as medicines.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">iv.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
patent system is expensive and increases costs on the consumers. The cost of
challenging a patent thorough legal process is high.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">v.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
cost of innovation that never takes place because of the flawed patent system
is incalculable. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">vi.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
article rely extensively on a book &#8216;The Case Against Patents&#8217; by two economists
Michele Boldrin and David Levine, compiling the research done so far, arguing
that patents are neither good at rewarding innovation nor help in real spread
of technology. After analyzing 23 studies carried out in the 20<sup>th</sup>
century on the patent system, they found &#8220;weak or no evidence that strengthening
of patent regimes increases innovation&#8221;. &nbsp;All it does is to get more patents filed,
which is not the same thing as innovation.&nbsp;</span><span style="font-size: 14pt; line-height: 107%;">The
main arguments of the book are summarized in the article as below:</span><br />
<span style="font-size: 14pt; line-height: 107%;"><br /></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 1.0in; mso-add-space: auto; mso-list: l1 level2 lfo1; text-align: justify; text-indent: -.25in;">
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">a.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">Evidence suggest that 19<sup>th</sup>
century countries that lacked patent systems were no less innovative than those
which had them.<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 1.0in; mso-add-space: auto; mso-list: l1 level2 lfo1; text-align: justify; text-indent: -.25in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">b.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">An exception to the general finding
only goes to prove the rule proposed that patents per se do not promote
innovation. The exception is the case of Taiwan&#8217;s 1986 patent reforms. After
the reforms that strengthened Taiwan&#8217;s patent system, the R&amp;D spending in
the country went up and more American patents were granted to Taiwanese
nationals. The article argues that this evidence show only that the countries
with weaker patent protection can divert investment and R&amp;D spending to
their territories by strengthening it. It does not demonstrate any increase in
worldwide R&amp;D spending or innovation. &nbsp;<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 1.0in; mso-add-space: auto; mso-list: l1 level2 lfo1; text-align: justify; text-indent: -.25in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">c.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">Expansion of patent system do not
bring about more innovation as evidenced from US experience. In 1970, US
extended patent protection to sexually reproducing plants. Studies on wheat
showed that this measure did not lead to greater research spending or increase
in yield. Even after extending patent protection to all biotech products in the
1980&#8217;s, the productivity of agriculture in US rose only at the same rate as
before. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 1.0in; mso-add-space: auto; mso-list: l1 level2 lfo1; text-align: justify; text-indent: -.25in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">d.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The rate of innovation show little
relation to patents. In industries from chemicals to computer software, waves
of innovation began with lots of participants. Patents started to get filed
only years later, once the spurt of innovation die down the incumbents in the
maturing industry seek to exclude new entrants as well as to protect themselves
from their rivals law suits. The real cause of patents is competition and is
only a result of innovation and not the cause of it. The patent system is good
for incumbents for fending off competition and not in public interest of promoting
innovation. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 1.0in; mso-add-space: auto; mso-list: l1 level2 lfo1; text-align: justify; text-indent: -.25in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">e.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The system may be offering benefits
to some start-ups with little access to capital but having new ideas but not s
in mature industries like aerospace and car making. In such industries, the
patent on technologies is only one of the component of creating a world beating
innovative product. The article cites the cases of market leadership of BMW and
Boeing which Chinese companies are unable to crack. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 1.0in; mso-add-space: auto; mso-list: l1 level2 lfo1; text-align: justify; text-indent: -.25in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">f.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">In some sectors like the
pharmaceuticals, the argument for continuation of patent is strong due to high
initial cost. Here also, evidence do not stand up to the claim of patents
fostering innovation. Till 1967 German companies could only have process
patents. But they produced more innovation than the British ones which enjoyed
product patents. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">vii.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
Economist argues for a top to bottom reexamination of whether patents and other
forms of intellectual property protection do their job and whether they deserve
to exist. &nbsp;It notes that outright abolition
proposals may create issues in terms of ethics of property rights. It points
out that no property rights are absolute, citing examples of demolishing houses
to make way for roads, taking money through taxation, and putting controls on
land use. In these cases a balance is struck between claim of the individual
and that of the society.&nbsp; It says that
with ideas, the argument that the government should force the owners is strong.
<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .75in; mso-add-space: auto; mso-list: l1 level1 lfo1; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">viii.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
Economist put the argument of free riding upside down. &nbsp;Free riding problem on ideas is the strongest
argument for providing property rights, because the imitator can reproduce the
idea, once created, without investment. It says sharing will lead to extra
innovation. Ideas overlap and innovations depend on earlier advances, for
example, there will be no Iphone without touchscreen. The signs are that innovation
today is less about entirely novel breakthroughs but more about clever
combinations and extension of existing ideas. Therefore free riding has value
in fostering innovation. Open source software including the Android operating
system are clear examples.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<b><span style="font-size: 14.0pt; line-height: 107%;"><br /></span></b></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<b><span style="font-size: 14.0pt; line-height: 107%;">Suggestions for Reforming Patent System</span></b><span style="font-size: 14.0pt; line-height: 107%;">:<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">The Economist cautions the reformists
that they should be aware of their own limitations. &nbsp;As innovation is complex. At the same breath
it points out that the current regime is susceptible to lobbying and plea of
special interests. &nbsp;&nbsp;A &#8216;clear and rough and ready patent system is
better than a complex and an elegant one. In government as in invention, simplicity
is strength (Highly desirable but easier said than done as anyone involved in
policy making knows. Anyone other than Economist saying this would have been
dragged down and beaten up).<o:p></o:p></span><br />
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">The Economist gives the following
suggestion for reform:<o:p></o:p></span><br />
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin-left: .75in; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -.5in;">
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">i.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
patents should come with a &#8220;use it or lose it&#8221; rule, so that they expire if the
invention is not brought to market. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">ii.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">Patents
should be easier to challenge without the expense of a full blown court case. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">iii.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
burden of proof for overturning a patent in a court should be lowered. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">iv.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">The
requirement that ideas should be non-obvious should be strengthened. Economists
states that Apple should not be granted patents for rectangular tablets with
rounded corners and nor Twitter the patent on &#8216;pull to refresh&#8217;. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: .75in; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">v.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">Governments
should gradually reduce the term of patent protection. 20 year is a long term
for patent. In fast moving industries, governments should gradually bring down
the length of patent. The Economist argues that even the pharmaceutical firms could
live with shorter patents if the regulatory regime gives faster approvals. <o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: .75in; mso-add-space: auto; mso-list: l0 level1 lfo2; text-align: justify; text-indent: -.5in;">
<span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><br /></span>
<!--[if !supportLists]--><span style="font-size: 14.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">vi.<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="font-size: 14.0pt; line-height: 107%;">Experiments
with other forms of financing innovation should could be run alongside the
patent system. It beseeches the defenders of the Patent system to do so in
their own backyard.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<b><span style="font-size: 14.0pt; line-height: 107%;"><br /></span></b></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<b><span style="font-size: 14.0pt; line-height: 107%;">Observations:<o:p></o:p></span></b></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<b><span style="font-size: 14.0pt; line-height: 107%;">What the Economist did not say:</span></b></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14.0pt; line-height: 107%;">One is disappointed that a critique
as comprehensive as what The Economist has done has left out one of the main
challenge in driving innovation for large populations. Patents drive innovation
only in those areas where market forces are active. It fails to drive
innovation in market failure situations. Take the example of neglected tropical
infectious diseases which affect vast segments of population in the tropics.
These tropical infectious diseases are called neglected because the pharmaceutical
industry which drives innovation does not see profits in them. It is a clear
example of incalculable cost of innovation that never takes place due to the
patent system. The patent system is inequitable in itself. Some suggestions
proposed by The Economist, like different modes of financing innovation could
address this. There are working examples of product development partnerships in
neglected diseases like <a href="http://www.tballiance.org/" target="_blank">TB Alliance</a> and <a href="http://www.mmv.org/" target="_blank">MMV</a>, <a href="http://www.dndi.org/" target="_blank">DnDi</a>,
<a href="http://www.gavi.org/" target="_blank">Gavi</a> and many others which goes on to show that an alternative system of financing
innovation exist in areas where patents do not work.</span><br />
<b style="text-align: justify;"><span style="font-size: 14.0pt; line-height: 107%;"><br /></span></b>
<b style="text-align: justify;"><span style="font-size: 14.0pt; line-height: 107%;">Compulsory License</span></b><br />
<span style="font-size: 14pt; line-height: 107%; text-align: justify;"><br /></span>
<span style="font-size: 14pt; line-height: 107%; text-align: justify;">The Economist argues that property
rights are not absolute. The state can place restrictions on property rights in
public interest. There are extensive arguments about wide sharing of ideas and
governments have recognized the limits on the patent system. Yet, it shy away
from mentioning about the TRIPS recognized too of compulsory license in public
interest. To be fair, there is an indirect reference to compulsory license
while discussing the US Federal Trade Commission&#8217;s recommendation to President Franklin
Roosevelt to replace patent system with compulsory licensing.</span><br />
<span style="font-size: 14pt; line-height: 107%; text-align: justify;"><br /></span>
<span style="font-size: 14pt; line-height: 107%; text-align: justify;">How can any article which discusses the
thereat to innovation posed by the patent system and list out some outlandish
(and some not so outlandish) solutions not even discuss this tool available in
the existing law?&nbsp;</span></div>
<br />
<div class="MsoNormal" style="text-align: justify;">
<b>Conclusion</b><br />
<b><br /></b>
<br />
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14pt; line-height: 19.973331451416px;">The Economist has not said anything really new or path breaking. What has been listed are well known issues and the solutions are also known ones. &nbsp;<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14pt; line-height: 19.973331451416px;"><br /></span></div>
<div class="MsoNormal" style="margin-left: .25in; text-align: justify;">
<span style="font-size: 14pt; line-height: 19.973331451416px;">The difference is only this &#8211; The Economist,&nbsp;</span><span style="font-size: 18.6666660308838px; line-height: 19.973331451416px;">the champion, mouthpiece and lead advocate of free market capitalism&nbsp;</span><span style="font-size: 14pt; line-height: 19.973331451416px;">is saying this. One can only hope that the world sits up and notice.</span></div>
</div>
</div>
<div style='clear: both;'></div>
</div>
<div class='post-footer'>
<div class='post-footer-line post-footer-line-1'>
<span class='post-author vcard'>
Posted by
<span class='fn' itemprop='author' itemscope='itemscope' itemtype='http://schema.org/Person'>
<meta content='https://www.blogger.com/profile/12006645854589278188' itemprop='url'/>
<a class='g-profile' href='https://www.blogger.com/profile/12006645854589278188' rel='author' title='author profile'>
<span itemprop='name'>Zakir Thomas</span>
</a>
</span>
</span>
<span class='post-timestamp'>
at
<meta content='http://innovip.blogspot.com/2015/08/the-economist-decries-patent-system.html' itemprop='url'/>
<a class='timestamp-link' href='http://innovip.blogspot.com/2015/08/the-economist-decries-patent-system.html' rel='bookmark' title='permanent link'><abbr class='published' itemprop='datePublished' title='2015-08-13T08:53:00-07:00'>8:53 AM</abbr></a>
</span>
<span class='reaction-buttons'>
</span>
<span class='post-comment-link'>
<a class='comment-link' href='http://innovip.blogspot.com/2015/08/the-economist-decries-patent-system.html#comment-form' onclick=''>
1 comment:
    </a>
</span>
<span class='post-backlinks post-comment-link'>
</span>
<span class='post-icons'>
<span class='item-control blog-admin pid-946377361'>
<a href='https://www.blogger.com/post-edit.g?blogID=4174420951068114981&postID=4036545927943992773&from=pencil' title='Edit Post'>
<img alt='' class='icon-action' height='18' src='//img2.blogblog.com/img/icon18_edit_allbkg.gif' width='18'/>
</a>
</span>
</span>
<div class='post-share-buttons goog-inline-block'>
<a class='goog-inline-block share-button sb-email' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=4036545927943992773&target=email' target='_blank' title='Email This'><span class='share-button-link-text'>Email This</span></a><a class='goog-inline-block share-button sb-blog' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=4036545927943992773&target=blog' onclick='window.open(this.href, "_blank", "height=270,width=475"); return false;' target='_blank' title='BlogThis!'><span class='share-button-link-text'>BlogThis!</span></a><a class='goog-inline-block share-button sb-twitter' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=4036545927943992773&target=twitter' target='_blank' title='Share to Twitter'><span class='share-button-link-text'>Share to Twitter</span></a><a class='goog-inline-block share-button sb-facebook' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=4036545927943992773&target=facebook' onclick='window.open(this.href, "_blank", "height=430,width=640"); return false;' target='_blank' title='Share to Facebook'><span class='share-button-link-text'>Share to Facebook</span></a><a class='goog-inline-block share-button sb-pinterest' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=4036545927943992773&target=pinterest' target='_blank' title='Share to Pinterest'><span class='share-button-link-text'>Share to Pinterest</span></a><div class='goog-inline-block google-plus-share-container'><g:plusone source='blogger:blog:plusone' href='http://innovip.blogspot.com/2015/08/the-economist-decries-patent-system.html' size='medium' width='300' annotation='inline'/></div>
</div>
</div>
<div class='post-footer-line post-footer-line-2'>
<span class='post-labels'>
</span>
</div>
<div class='post-footer-line post-footer-line-3'>
<span class='post-location'>
</span>
</div>
</div>
</div>
</div>

          </div></div>
        

          <div class="date-outer">
        
<h2 class='date-header'><span>Saturday, August 1, 2015</span></h2>

          <div class="date-posts">
        
<div class='post-outer'>
<div class='post hentry uncustomized-post-template' itemprop='blogPost' itemscope='itemscope' itemtype='http://schema.org/BlogPosting'>
<meta content='https://i.imgur.com/MPQz5mp.png' itemprop='image_url'/>
<meta content='4174420951068114981' itemprop='blogId'/>
<meta content='3385522113424663910' itemprop='postId'/>
<a name='3385522113424663910'></a>
<h3 class='post-title entry-title' itemprop='name'>
<a href='http://innovip.blogspot.com/2015/08/the-curious-copyright-case-of-happy.html'>The Curious Copyright Case of Happy Birthday Song</a>
</h3>
<div class='post-header'>
<div class='post-header-line-1'></div>
</div>
<div class='post-body entry-content' id='post-body-3385522113424663910' itemprop='description articleBody'>
<div dir="ltr" style="text-align: left;" trbidi="on">
<div align="center" class="MsoNormal" style="text-align: center;">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">You might
find it hard to believe, the ubiquitous Happy Birthday song which we sing in
all birthdays is claimed to be under copyright protection, which earns Warner
Music a licensing royalty of about $2 Million per year. <o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14pt; line-height: 107%;">A dispute that
is ongoing in a New York Court is&nbsp;</span><span style="font-size: 18.6666660308838px; line-height: 19.9733333587647px;">unraveling</span><span style="font-size: 14pt; line-height: 107%;">&nbsp;its interesting story.<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">The claim of
original creation of "Happy Birthday" song is with two sisters from
Kentucky,&nbsp;US, Mildred Jane&nbsp;Hill and Patty Smith Hill who were Kindergarten
teachers. Mildred, born in 1859, was a concert pianist and composer. They
composed a song of greeting for the children and Mildred came up with the melody
(which we now know as the tune of "Happy Birthday") for teachers to
use in welcoming students to the class each day:<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">Good morning
to you,<br />
Good morning to you,<br />
Good morning, dear children,<br />
Good morning to all.<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">During the
19<sup>th</sup> century, birthday celebrations as we know it today were not so
popular. To quote from <a href="http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1111624">Prof Brauneis&#8217; essay</a>&nbsp;(aptly titled 'Copyright and the World's Most Popular Song'): <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-left: .5in;">
<span style="font-size: 14.0pt; line-height: 107%;">According to scholar Elizabeth Pleck, birthday parties did
not become common even among wealthy Americans until the late 1830s; modern
birthday cakes emerged after 1850; and peer-culture birthday parties, involving
children of the same age as the child whose birthday was being celebrated,
emerged between 1870 and 1920, after American urban public schools became
age-graded.<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">The history
of how &#8220;Good morning to you&#8221; song turned into &#8220;Happy Birthday to you&#8221; is unclear
and that adds o the intrigue of the ongoing copyright dispute. No one knows who
wrote the words to "Happy Birthday to You" and put them to Mildred
Hill's melody, or when it happened. The lyrics to "Happy Birthday to
You" began appearing in conjunction with the "Good Morning to
All". One of the earliest known book to include that combination of lyrics
and melody is&nbsp;<i>The Beginners' Book of Songs</i>, published by the Cable
Company in 1912.<br /><br />
</span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">A Broadway musical called Thousand Cheers used Happy Birthday version of Good
Morning to you without the Good Morning to you part. The Hill sisters sued the
producers for copyright infringement of their song claiming $250, at that time.
This lawsuit was apparently settled.&nbsp;</span><span style="font-size: 14pt; line-height: 107%;">It was the Thousand
Cheer show which was immensely popular which made the song a household ritual
in all birthday parties. </span><a href="http://time.com/3976577/happy-birthday-copyright-history/" style="font-size: 14pt; line-height: 107%;">Time</a><span style="font-size: 14pt; line-height: 107%;">&nbsp;reports that the song and the&nbsp;</span><span style="font-size: 18.6666660308838px; line-height: 19.9733333587647px;">practice</span><span style="font-size: 14pt; line-height: 107%;">&nbsp;of&nbsp;</span><span style="font-size: 18.6666660308838px; line-height: 19.9733333587647px;">organizing</span><span style="font-size: 14pt; line-height: 107%;">&nbsp;birthday parties emerged around the same time, in the
beginning of 20</span><sup style="font-size: 14pt; line-height: 107%;">th</sup><span style="font-size: 14pt; line-height: 107%;"> century &#8211; &#8216;the song and the occasion to sing it
came up together&#8217;.&nbsp;</span><span style="font-size: 14pt; line-height: 107%;">&#8220;Happy
Birthday to You&#8221; became the standard birthday song in the period between 1915
and 1935. A statement of the American Society of Composers, Authors and
Publishers (ASCAP) in 1999 claimed that &#8220;Happy Birthday to You&#8221; was the most
popular song of the twentieth century.</span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">In 1935, a
music publisher&nbsp;Clayton F.&nbsp;Summy Company, published "Happy
Birthday (to You)" with the authorization of Jessica Hill in 1935 and
filed copyright registrations for several versions of the song. This company
which owns the copyright changed hands and is currently owned by Warner Music
Group which collects about $ 2 Million in royalties per year.&nbsp;<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">The song could
claim to still remain in copyright domain due to peculiarities of the US
copyright law. Under the laws in effect at the time of publication copyright
would have expired after one 28-year term and a renewal of similar length,
falling into public domain by 1991. However, the Copyright Act of 1976 extended
the term of copyright protection to 75 years from date of publication, and the
Copyright Term Extension Act of 1998 added another 20 years, so under current
law the copyright protection of "Happy Birthday to You" will remain
intact <a href="http://www.snopes.com/music/songs/birthday.asp#JjLC8jHuDSt32XLE.99">until at least 2030</a>. <o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">In June
2013, a film company working on a documentary about "Happy Birthday to
You" filed a class action lawsuit to invalidate Warner Musics claim to
copyright ownership of the song. It is this case that is making news. The New
York Times reported that Lawyers for a filmmaker in New York said they had
discovered &#8220;smoking-gun&#8221; evidence that the song &#8220;Happy Birthday to You&#8221; should
no longer be subject to copyright restrictions. The court filing argues that
copyright law at the time required the work to exhibit a copyright notice to
claim copyright protection. This was not found in a 1922 publication without which
the work was <a href="http://www.snopes.com/music/songs/birthday.asp#JjLC8jHuDSt32XLE.99">&#8220;interjected irrevocably into the public domain&#8221;</a>.</span><span style="font-size: 14pt; line-height: 107%;">&nbsp;The following image has been produced in the court to substantiate this claim as reported by <a href="https://www.techdirt.com/articles/20150727/16042931768/happy-birthday-copyright-bombshell-new-evidence-warner-music-previously-hid-shows-song-is-public-domain.shtml">Techdirt</a>. &nbsp;</span></div>
<div class="MsoNormal">
<span style="font-size: 14pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<img src="https://i.imgur.com/MPQz5mp.png" /></div>
<div class="MsoNormal">
<span style="font-size: 14pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14pt; line-height: 107%;">The actions of Warner Music, it is claimed, was to deliberately suppress the above evidence. We have to wait to hear what the court has to say on this matter.&nbsp;</span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">
<!--[if !supportLineBreakNewLine]--><br />
<!--[endif]--><o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">So do you
have to worry if you sing Happy Birthday song in India?&nbsp;</span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">No, not at all. The
song is in public domain in India due to an interesting provision of copyright
law. &nbsp;</span><span style="font-size: 14pt; line-height: 107%;">Though
Copyright enjoys international protection, the duration of copyright, comes
under the national treatment principle. In India, the copyright term is till 60
years from the year of publication. The Happy Birthday song which was published
in 1912 is clearly outside copyright domain in India.&nbsp;</span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;"><br /></span></div>
<div class="MsoNormal">
<span style="font-size: 14.0pt; line-height: 107%;">However, in
the United States Warner Music asserts copyright and till a court invalidates this
claim of copyright ownership, the song "Happy Birthday to You"
remains in a copyright-protected state! But as per the evidence that are being placed before the court, the US$ 2 Million that Warner Music earns seems to be without legal basis.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<br />
<div class="MsoNormal">
<span style="font-size: 14pt; line-height: 107%;">This is a clear case of Copyright overreach. It is such&nbsp;</span><span style="font-size: 18.6666660308838px; line-height: 19.9733333587647px;">behavior</span><span style="font-size: 14pt; line-height: 107%;">&nbsp;that puts the entire system to disrepute in the eyes of the law abiding common-folk.</span></div>
</div>
<div style='clear: both;'></div>
</div>
<div class='post-footer'>
<div class='post-footer-line post-footer-line-1'>
<span class='post-author vcard'>
Posted by
<span class='fn' itemprop='author' itemscope='itemscope' itemtype='http://schema.org/Person'>
<meta content='https://www.blogger.com/profile/12006645854589278188' itemprop='url'/>
<a class='g-profile' href='https://www.blogger.com/profile/12006645854589278188' rel='author' title='author profile'>
<span itemprop='name'>Zakir Thomas</span>
</a>
</span>
</span>
<span class='post-timestamp'>
at
<meta content='http://innovip.blogspot.com/2015/08/the-curious-copyright-case-of-happy.html' itemprop='url'/>
<a class='timestamp-link' href='http://innovip.blogspot.com/2015/08/the-curious-copyright-case-of-happy.html' rel='bookmark' title='permanent link'><abbr class='published' itemprop='datePublished' title='2015-08-01T08:11:00-07:00'>8:11 AM</abbr></a>
</span>
<span class='reaction-buttons'>
</span>
<span class='post-comment-link'>
<a class='comment-link' href='http://innovip.blogspot.com/2015/08/the-curious-copyright-case-of-happy.html#comment-form' onclick=''>
No comments:
    </a>
</span>
<span class='post-backlinks post-comment-link'>
</span>
<span class='post-icons'>
<span class='item-control blog-admin pid-946377361'>
<a href='https://www.blogger.com/post-edit.g?blogID=4174420951068114981&postID=3385522113424663910&from=pencil' title='Edit Post'>
<img alt='' class='icon-action' height='18' src='//img2.blogblog.com/img/icon18_edit_allbkg.gif' width='18'/>
</a>
</span>
</span>
<div class='post-share-buttons goog-inline-block'>
<a class='goog-inline-block share-button sb-email' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3385522113424663910&target=email' target='_blank' title='Email This'><span class='share-button-link-text'>Email This</span></a><a class='goog-inline-block share-button sb-blog' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3385522113424663910&target=blog' onclick='window.open(this.href, "_blank", "height=270,width=475"); return false;' target='_blank' title='BlogThis!'><span class='share-button-link-text'>BlogThis!</span></a><a class='goog-inline-block share-button sb-twitter' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3385522113424663910&target=twitter' target='_blank' title='Share to Twitter'><span class='share-button-link-text'>Share to Twitter</span></a><a class='goog-inline-block share-button sb-facebook' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3385522113424663910&target=facebook' onclick='window.open(this.href, "_blank", "height=430,width=640"); return false;' target='_blank' title='Share to Facebook'><span class='share-button-link-text'>Share to Facebook</span></a><a class='goog-inline-block share-button sb-pinterest' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3385522113424663910&target=pinterest' target='_blank' title='Share to Pinterest'><span class='share-button-link-text'>Share to Pinterest</span></a><div class='goog-inline-block google-plus-share-container'><g:plusone source='blogger:blog:plusone' href='http://innovip.blogspot.com/2015/08/the-curious-copyright-case-of-happy.html' size='medium' width='300' annotation='inline'/></div>
</div>
</div>
<div class='post-footer-line post-footer-line-2'>
<span class='post-labels'>
</span>
</div>
<div class='post-footer-line post-footer-line-3'>
<span class='post-location'>
</span>
</div>
</div>
</div>
</div>

          </div></div>
        

          <div class="date-outer">
        
<h2 class='date-header'><span>Sunday, January 4, 2015</span></h2>

          <div class="date-posts">
        
<div class='post-outer'>
<div class='post hentry uncustomized-post-template' itemprop='blogPost' itemscope='itemscope' itemtype='http://schema.org/BlogPosting'>
<meta content='4174420951068114981' itemprop='blogId'/>
<meta content='3280463445417229696' itemprop='postId'/>
<a name='3280463445417229696'></a>
<h3 class='post-title entry-title' itemprop='name'>
<a href='http://innovip.blogspot.com/2015/01/copyright-extremism-denying-access-to.html'>Copyright Extremism: Denying Access to Information</a>
</h3>
<div class='post-header'>
<div class='post-header-line-1'></div>
</div>
<div class='post-body entry-content' id='post-body-3280463445417229696' itemprop='description articleBody'>
<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Can you be
threatened with criminal charges and consequent jail term for sharing a
research paper online? &#8216;Hell, no!&#8217;, would most likely be your answer. You are
wrong, as per the law in many countries! <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Georgia, Times New Roman, serif;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">One of the
widely discussed copyright cases in 2014 was that of Diego Gomez, 26, researcher
in Columbia working on biodiversity and the conservation of reptiles and
amphibians in the South American region. A couple of years ago, he shared a
research paper that he wanted to bring to the notice of other researchers in
his field on Scribd. And this cost him a price! He is now facing a lawsuit
filed by the author of the paper for violation of copyright. Under the Columbian
copyright law, Gomez could be sent to prison for up to eight years and face
crippling monetary fines. The case of Gomez brings to focus the issue of access
to knowledge and information. You may read more about this case </span><a href="https://www.eff.org/deeplinks/2014/07/colombian-student-faces-prison-charges-sharing-academic-article-online"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">here</span></a><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">This is an
extreme case. But it is at the extremes where the real test of the law lies.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Georgia, Times New Roman, serif;"><b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">The Provisions of the Law</span></b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"> <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">At the core
of copyright protection is the balance between the economic rights of the
author and the need of the public to access information. The most basic
copyright treaty, the Berne Convention recognizes this. Therefore, while
granting rights to the authors, the law provides for limitations and exceptions
to the rights. These are generally known as fair use provisions. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">The basic
principle is as follows. The authors of literary works (research paper in this
case) have the exclusive right of reproduction and distribution of such works
in all media, including online. The law places limitations on this right of the
author. Since the laws of different countries may vary the basic provision in
Berne Convention is reproduced below:<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Article 9: Right
of Reproduction: <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">&nbsp;(1) Authors of literary and artistic works
protected by this Convention shall have the exclusive right of authorizing the
reproduction of these works, in any manner or form. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">(2) It shall
be a matter for legislation in the countries of the Union to permit the
reproduction of such works in certain special cases, provided that such
reproduction does not conflict with a normal exploitation of the work and does
not unreasonably prejudice the legitimate interests of the author.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Article 9 (2)
permits countries to frame laws to allow reproduction of works under the three
step rule, namely:<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin-left: 56.25pt; mso-add-space: auto; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Georgia, Times New Roman, serif;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">(1)<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;
</span></span><!--[endif]--><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">Such reproduction occurs in special
cases;<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 56.25pt; mso-add-space: auto; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Georgia, Times New Roman, serif;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">(2)<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;
</span></span><!--[endif]--><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">such reproduction does not conflict
with a normal exploitation of the work;<o:p></o:p></span></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 56.25pt; mso-add-space: auto; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;">
<!--[if !supportLists]--><span style="font-family: Georgia, Times New Roman, serif;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">(3)<span style="font-size: 7pt; font-stretch: normal; line-height: normal;">&nbsp;&nbsp;
</span></span><!--[endif]--><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">&nbsp;and does not unreasonably prejudice the
legitimate interests of the author<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">The copyright
law of most countries provides research use of copyrighted material as fair
use. This is because research use is regarded as a special case, which does not
affect normal exploitation of the work. TRIPS follow similar provisions. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Columbian Double Whammy<o:p></o:p></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Columbia, a
civil law jurisdiction, has some peculiarities in its copyright law. The
copyright violations are treated as criminal violations, unlike many other
jurisdictions including US where it is a civil offence. Columbia modified its
law and tightened the copyright regime following the conclusion of the US trade
agreement with Columbia in 2006.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">The
exceptions available under the Columbia's copyright law were outdated. While
tightening the law to meet the bilateral agreement with US, Columbia failed to
extend the exceptions permitting fair use of its work. Therefore, just one side
of the law got stringent. Columbia failed to adopt the fair use provisions
which US permits in its copyright law, while the rights were tightened. Some,
like <a href="https://www.eff.org/deeplinks/2014/10/open-access-week-international-copyright-policy-laundering-and-ongoing-war-access">EFF</a>
has ascribed the restrictive provisions of the trade agreements as the reason
limiting the nation&#8217;s ability to make changes to the fair use provisions. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Bilateral Trade Deals, Beware!<o:p></o:p></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Copyright
laws are municipal laws. International treaties provide only certain minimum
standards. These will have to be legislated into law (except in jurisdictions
where treaties have the force of law). This gives the freedom to nation states
to craft its policies. Also, the treaties prescribe only minimum standards and
nation states are free to provide stronger protection. Therefore the tougher
law of Columbia does not violate any conventions. It only limits the ability of
its citizens to access works.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Georgia, Times New Roman, serif;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-family: Georgia, Times New Roman, serif;"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">The national
laws are normally passed after a legislative process. International treaties
are adopted after extensive studies and negotiations. Such processes ensure a
balance in approach in such instruments. However, trade agreements are
concluded for protecting commercial interest and are not subjected to any such
process and often lack balance. It is therefore in the interest of the
countries entering into such bilateral agreements to modify their laws to
protect the interest of its people. This </span><a href="https://www.eff.org/deeplinks/2014/10/open-access-week-international-copyright-policy-laundering-and-ongoing-war-access"><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">EFF</span></a><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;">
post states that the copyright law of Colombia has a closed list of fair
dealing exceptions that must be passed legislatively, rather than the
open-ended, flexible exceptions permitted by other fair use systems (like in
the US). <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US"><span style="font-family: Georgia, Times New Roman, serif;"><span style="font-size: 12pt; line-height: 115%;">It is
estimated that there are about a dozen bilateral US trade deals that contain
copyright provisions that echo US copyright law. But the trade treaties are
without the public interest protections that are built into US law, such as
fair use. Therefore the countries that adopt such trade treaties need to take appropriate remedial measures.</span></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">The Indian Law<o:p></o:p></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Indian
copyright law provides for fair dealing of copyright works under Section 52 of
the Copyright Act 1957. Section 52 (1) (a) provides that fair dealing with any
work for private or personal use, including research shall not constitute
infringement of copyright. The Explanation to this clause clarifies that the
provision has been extended to digital environment. Therefore Indian law
provides for fair use on the internet. The key words to be noted are &#8216;private
or personal use, including research&#8217;. The key question is whether sharing
online is private or not. While sharing copyright works with a limited private
group is permitted, sharing online publicly seems to fall afoul of the law.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Fight for Fair Use:<o:p></o:p></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Copyright
laws are designed to protect the rights of the author and provide reasonable
access to the public for works. The provisions of the law are restrictive. The rightholder&#8217;s
always try to push the envelope to expand the right. It is for the users to
assert their right as well. Unless the users fight for the fair use rights,
they will lose their precious freedoms. If users are not alert about their
rights, they might face Diego Gomez&#8217;s fate. <o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></b></div>
<div class="MsoNormal" style="text-align: justify;">
<b><span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">Open Access:<o:p></o:p></span></span></b></div>
<br />
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;"><br /></span></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span lang="EN-US" style="font-size: 12.0pt; line-height: 115%; mso-ansi-language: EN-US;"><span style="font-family: Georgia, Times New Roman, serif;">It is due to
the restrictive conditions of access to copyright works that Open Access
movement has attracted the attention of researchers. Open access (OA) means
unrestricted online access to peer-reviewed scholarly research. Those
researchers who believe in access to knowledge as the cornerstone of progress, should
opt for publishing in Open Access format.</span> &nbsp;<b><o:p></o:p></b></span></div>
</div>
<div style='clear: both;'></div>
</div>
<div class='post-footer'>
<div class='post-footer-line post-footer-line-1'>
<span class='post-author vcard'>
Posted by
<span class='fn' itemprop='author' itemscope='itemscope' itemtype='http://schema.org/Person'>
<meta content='https://www.blogger.com/profile/12006645854589278188' itemprop='url'/>
<a class='g-profile' href='https://www.blogger.com/profile/12006645854589278188' rel='author' title='author profile'>
<span itemprop='name'>Zakir Thomas</span>
</a>
</span>
</span>
<span class='post-timestamp'>
at
<meta content='http://innovip.blogspot.com/2015/01/copyright-extremism-denying-access-to.html' itemprop='url'/>
<a class='timestamp-link' href='http://innovip.blogspot.com/2015/01/copyright-extremism-denying-access-to.html' rel='bookmark' title='permanent link'><abbr class='published' itemprop='datePublished' title='2015-01-04T09:02:00-08:00'>9:02 AM</abbr></a>
</span>
<span class='reaction-buttons'>
</span>
<span class='post-comment-link'>
<a class='comment-link' href='http://innovip.blogspot.com/2015/01/copyright-extremism-denying-access-to.html#comment-form' onclick=''>
No comments:
    </a>
</span>
<span class='post-backlinks post-comment-link'>
</span>
<span class='post-icons'>
<span class='item-control blog-admin pid-946377361'>
<a href='https://www.blogger.com/post-edit.g?blogID=4174420951068114981&postID=3280463445417229696&from=pencil' title='Edit Post'>
<img alt='' class='icon-action' height='18' src='//img2.blogblog.com/img/icon18_edit_allbkg.gif' width='18'/>
</a>
</span>
</span>
<div class='post-share-buttons goog-inline-block'>
<a class='goog-inline-block share-button sb-email' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3280463445417229696&target=email' target='_blank' title='Email This'><span class='share-button-link-text'>Email This</span></a><a class='goog-inline-block share-button sb-blog' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3280463445417229696&target=blog' onclick='window.open(this.href, "_blank", "height=270,width=475"); return false;' target='_blank' title='BlogThis!'><span class='share-button-link-text'>BlogThis!</span></a><a class='goog-inline-block share-button sb-twitter' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3280463445417229696&target=twitter' target='_blank' title='Share to Twitter'><span class='share-button-link-text'>Share to Twitter</span></a><a class='goog-inline-block share-button sb-facebook' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3280463445417229696&target=facebook' onclick='window.open(this.href, "_blank", "height=430,width=640"); return false;' target='_blank' title='Share to Facebook'><span class='share-button-link-text'>Share to Facebook</span></a><a class='goog-inline-block share-button sb-pinterest' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=3280463445417229696&target=pinterest' target='_blank' title='Share to Pinterest'><span class='share-button-link-text'>Share to Pinterest</span></a><div class='goog-inline-block google-plus-share-container'><g:plusone source='blogger:blog:plusone' href='http://innovip.blogspot.com/2015/01/copyright-extremism-denying-access-to.html' size='medium' width='300' annotation='inline'/></div>
</div>
</div>
<div class='post-footer-line post-footer-line-2'>
<span class='post-labels'>
</span>
</div>
<div class='post-footer-line post-footer-line-3'>
<span class='post-location'>
</span>
</div>
</div>
</div>
</div>

          </div></div>
        

          <div class="date-outer">
        
<h2 class='date-header'><span>Wednesday, August 13, 2014</span></h2>

          <div class="date-posts">
        
<div class='post-outer'>
<div class='post hentry uncustomized-post-template' itemprop='blogPost' itemscope='itemscope' itemtype='http://schema.org/BlogPosting'>
<meta content='4174420951068114981' itemprop='blogId'/>
<meta content='8447122701918047778' itemprop='postId'/>
<a name='8447122701918047778'></a>
<h3 class='post-title entry-title' itemprop='name'>
<a href='http://innovip.blogspot.com/2014/08/the-limits-of-patent-system.html'>The Limits of the Patent System</a>
</h3>
<div class='post-header'>
<div class='post-header-line-1'></div>
</div>
<div class='post-body entry-content' id='post-body-8447122701918047778' itemprop='description articleBody'>
<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><b>Do Patents Kill Innovation?</b></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Do
patents kill innovation? Evidence is piling up that they do. This time the
evidence is from the pharmaceutical industry itself. The strongest case for
patent has been made out in the pharmaceutical industry. Since pharmaceutical
research is inherently risky and requires substantial investment, it is argued
that the sector requires a strong patent protection. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">It is in cancer drug discovery that evidence has come out that patents destroy R&amp;D.
A <a href="http://economics.mit.edu/files/8651">paper</a>, &#8220;Do fixed patent
terms distort innovation? Evidence from cancer clinical trials&#8221; by Eric Budish
of University of Chicago, Benjamin N. Roin of Harvard Law School and Heidi
Williams of MIT demonstrates, through empirical study, how patent system distorts
R&amp;D for cancer therapy. The paper finds that patents generate distorted
R&amp;D incentives, in the case of cancer. Cancer research, particularly for
early stage cancer, which is curable, requires long clinical trials. Therefore
industry prefers to invest in R&amp;D for metastatic cancers, which requires
less duration trials, but the therapy may prolong the life by only a few months.
This is of significant concern from a medical perspective.<span style="mso-spacerun: yes;">&nbsp; </span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Surprisingly,
the authors note that there has been no empirical study on patent protection
and innovation. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="margin-left: 36.0pt; text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Although theoretical models often assume a relationship
between the strength of patent protection and the level of innovation, there is
a remarkable dearth of empirical evidence on this link. For example, <a href="http://www.nber.org/papers/w8977">Lerner</a> (2002) and <a href="http://www.nber.org/papers/w7066">Sakakibara and Branstetter</a> (2001)
find little evidence that stronger intellectual property rights induce more
innovation.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Patent
exclusivity is for a limited period of 20 years. There is usually a
considerable gap between the filing of patent of the invention and the ultimate
commercialisation. This may be referred to as a commercialisation lag. Normally
for a drug the commercialisation lag is estimated to be about 10-12 years.
Firms have to recoup their research investment and the profit during the patent
period. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Cancer
has a paradox from a patent perspective. The survival has to be measured over
long periods of time. To explain, let us understand the two types of cancer.
When it starts cancer is mostly localized (the primary site). At this stage it
could be curable in many cases. At an advanced stage, the cancer spreads to
other parts of the body. Metastatic cancer is a cancer that has spread from the
primary site, where it started, to other parts of the body. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">The
authors cite the example of two studies reported in New England Journal of
Medicine in 2011. A first study, de Bono et al. (2011), analyzed a treatment
for<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">metastatic
prostate cancer (an advanced stage of prostate cancer with a five-year survival
rate of the order of 20 percent). The study tracked patient survival for a
median time of 12.8 months, and estimated statistically significant
improvements in survival (a gain of 3.9 months of life on average). A second
study, Jones et al. (2011), analyzed a treatment for localized prostate cancer
(an early stage of prostate cancer with a five-year survival rate of the order
of 80 percent. The study tracked patient survival for a median time of 9.1
years, estimating statistically significant improvements in survival. Both the
above cases have different patient follow-up times and this translates into a
large difference in clinical trial length: 3 years for the metastatic cancer patient
trial versus 18 years for the localized patient trial. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">A
private for profit firm will not carry out a trial for 18 years and bring a drug
to the market when patent term itself is 20 years. As may be expected, the authors
found that a private firm funded the study of the metastatic cancer patients
with the shorter duration trial whereas the National Cancer Institute funded
the study of localized cancer patients requiring long duration.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">To
find a real cure for a primary cancer, R&amp;D is required over long periods of
time. To demonstrate that cancer is cured, you need longer clinical trials with
long commercialisation lag. The &#8216;for profit&#8217; firms have very little incentive
to do this. Therefore they focus on metastatic cancers that require only
shorter clinical trials, where cures would amount to prolonging the life by few
months.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Authors
of the paper analysed the data from a clinical trial registry that has
cataloged cancer clinical trials since the 1970s. They found the correlation
that privately financed trials favoured shorter survival terms. The authors
found that R&amp;D investments on cancer treatments are strongly negatively
correlated with expected survival time. They observed lower levels of R&amp;D
investment on inventions that required longer commercialization lags. This
coupled with corporate <a href="https://faculty.fuqua.duke.edu/~qc2/BA532/1989%20QJE%20Stein.pdf">short
termism</a> poses significant challenge to cancer research. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">They
also found that all six FDA-approved cancer prevention drugs (that are
under-incentivized by the patent system), either relied on the use of surrogate
endpoints for shorter trials or were approved on the basis of publicly financed
clinical trials.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">The
authors point out that in the pharmaceutical industry, &#8220;drugs treating patients
with short life expectancies can move through the clinical trials more quickly
-and thus receive longer effective patent terms - than drugs treating patients
with long life expectancies&#8221;. They provide several evidences showing patents
distorting cancer R&amp;D away from drugs targeting early-stage cancer patients
or cancer prevention to late stage management.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">In
essence, the innovation that happens is not what is medically mandated, but
driven by the industry&#8217;s ability to extract maximum during the patent term.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<b style="mso-bidi-font-weight: normal;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Another area where Patents are ineffective:
Neglected and Orphan Diseases<o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Patents
are a market driven tool. It works where there is a market from where it
enables recouping of investments. Where market is absent, patents do not
generate innovations.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Take
the case of orphan diseases and neglected diseases. Remember, the United States
is the largest pharmaceutical market of the world. Even there, if you have a
disease which does not command a huge market which interests pharmaceutical
companies, you don't have innovation. The <a href="http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/orphandrugact/default.htm">Orphan
Drugs Act</a> of US characterizes orphan diseases as those diseases that affect
small numbers of individuals residing in the United States that the diseases
and conditions are considered rare in the United States. It goes on to state
that:<o:p></o:p></span></div>
<div class="MsoListParagraphCxSpFirst" style="margin-left: 38.65pt; mso-add-space: auto; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt; text-justify: inter-ideograph;">
<!--[if !supportLists]--><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><span style="mso-list: Ignore;">&#183;<span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="color: black;">because so few
individuals are affected by any one rare disease or condition, a pharmaceutical
company which develops an orphan drug may reasonably expect the drug to
generate relatively small sales in comparison to the cost of developing the
drug and consequently to incur a financial loss;</span><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-left: 38.65pt; mso-add-space: auto; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt; text-justify: inter-ideograph;">
<!--[if !supportLists]--><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><span style="mso-list: Ignore;">&#183;<span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="color: black;">there is reason to
believe that some promising orphan drugs will not be developed unless changes
are made in the applicable Federal laws to reduce the costs of developing such
drugs and to provide financial incentives to develop such drugs; and</span><o:p></o:p></span></div>
<div class="MsoListParagraphCxSpLast" style="margin-left: 38.65pt; mso-add-space: auto; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt; text-justify: inter-ideograph;">
<!--[if !supportLists]--><span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><span style="mso-list: Ignore;">&#183;<span style="font-style: normal; font-variant: normal; font-weight: normal; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><!--[endif]--><span style="color: black;">it is in the public
interest to provide such changes and incentives for the development of orphan
drugs.</span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">This
enactment recognizes the limits of the patent system and therefore a policy instrument
other than patents have been used to spur innovation. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Compared
to the small number of patients affected by Orphan diseases, neglected diseases
affect a large number of individuals. Neglected Disease are mostly tropical
infectious diseases affecting a large number of people. They earn this
sobriquet as pharmaceutical companies generally neglect R&amp;D in them. Take
the case of Tuberculosis (TB). TB is second only to HIV as the leading
infectious disease mortality, worldwide. 1.5 million people died of TB in 2012
alone. Someone dies of TB every 25 seconds somewhere in the world. Yet the
current drugs in use for TB hail from the 1950&#8217;s and 1960&#8217;s. The therapy is
lengthy and toxic. No new drugs that shorten the regimen have been introduced
despite the enormous progress made by pharmaceutical industry during this time;
that is the story of innovation for neglected diseases. TB is only
illustrative. Malaria, dengue fever, dracunculiasis, leishmaniasis, lymphatic
filariasis, onchocerciasis, schistosomiasis, soil transmitted helminthiasis, trachoma
and trypanosomiasis, so the list goes on, all affecting the poor in the
tropical regions. These diseases may be affecting different parts of the world.
But they have one thing in common &#8211; no innovation.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">It
is in this sector that the 90-10 gap was noticed by the Commission on Health
Research for Development which published the report <a href="http://www.cohred.org/sites/default/files/ComReports_0.pdf"><span style="background: white; color: #663366;">Health Research: Essential Link to
Equity in Development</span></a>. 90% of the innovation in healthcare relates
to the diseases of a mere 10% of the population of the world. Pharmaceutical
companies who make substantial profits from global sale of drugs prefer
innovation in lifestyle diseases to that of neglected diseases. <span style="mso-bidi-font-family: &quot;Times New Roman&quot;; mso-fareast-font-family: &quot;Times New Roman&quot;;"><o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Patents
as a public policy tool has completely failed to drive innovation in neglected
diseases. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<b style="mso-bidi-font-weight: normal;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Limits of the Patent System<o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">All
these point to the limits of patent as an instrument of public policy to drive
innovation. It does not induce innovation in cancer nor does it in neglected or
orphan diseases. Patent induced innovation works only in a narrow space where
all other propitious conditions are present. Beyond this narrow market driven
space, say cancer or neglected diseases, it simply fails to drive innovation.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Patents
have been characterized by many as the &#8216;be all&#8217; and &#8216;end all&#8217; of innovation. There
are many who argue and even believe that patents are the sine qua non of
innovation. Provide the strictest of patent laws innovation will follow, so
goes the argument. This argument has been adopted, post TRIPS, by most
policymakers as a given. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">But
the reality is different. It is only one of the components of a complex ecosystem
that makes up the innovation ecosystem. We have a tendency to assume many more
functions for patents. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Patents
perform a limited function. Patent system is a market based mechanism for capital
accumulation. It acts as an instrument to grant a limited exclusivity to the
innovator for a limited period. It does not fix other gaps in the innovation
ecosystem and its presence on its own does not spur innovation. On its own it
does not attract either innovation or technology or investment. A
counterfactual proves this assertion. If it was indeed the case, some of the
sub Saharan African nations who have the strongest of the patent laws should
have been the most innovative as well. In any case, post TRIPS we have more or
less uniform patent laws around the world but that has not spread innovation or
investment across the world.<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Public
policy making is not always evidence based. That is the tragedy. It is most of
the time based on beliefs. And the predominant beliefs of the age always find
its place in the policies, without much evidence to support such beliefs, whether
good or bad. Sometimes evidence emerges to the contrary but they are ignored if
it is against the current belief. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Corporate
short termism and limits of patent puts a limit on humanities quest to find
cures for many diseases. There has to be other public policy instruments that would
drive and support innovation in cases where patent system does not work, or
worse, provide perverse innovation as in the case of cancer. <o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<b style="mso-bidi-font-weight: normal;"><span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Call for Reform<o:p></o:p></span></b></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;">Do
patents kill innovation? Even the conservative journal like The <a href="http://www.economist.com/blogs/freeexchange/2014/08/innovation">Economist</a>
thinks so. The Economist has recognized the limitations of the patent system
and has called for reform. This is what the <a href="http://www.economist.com/blogs/freeexchange/2014/08/innovation">Economist
says</a>:<o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><span style="color: #4a4a4a;">A one-size-fits-all patent system does not cater to the
specifics of innovation in the pharmaceutical industry. But tailoring patent
law may encourage lobbying and corruption. A careful<span class="apple-converted-space">&nbsp;</span></span><a href="http://www.economist.com/news/business/21591206-congress-takes-aim-patent-abusers-trolls-hill"><span style="border: 1pt none windowtext; color: #4a4a4a; padding: 0cm;">reform of the patent system is necessary</span></a><span style="color: #4a4a4a;">: outright abolition of patents will not be enough to save
cancer patients&#8217; lives.&nbsp;</span><span style="mso-bidi-font-family: &quot;Times New Roman&quot;; mso-fareast-font-family: &quot;Times New Roman&quot;;"><o:p></o:p></span></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif; font-size: large;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif;"><span style="font-size: large;">In
2014, we are moving to 20 years of TRIPS. If many in the developing world ask,
&#8220;what have we gained&#8221;, there is very little to answer to them in terms of
better medicines for their diseases. If we accept that all lives have equal
value,&nbsp; it is time for policy makers to
take a comprehensive look at innovation in the pharmaceutical sector and abhor
the myopic view that patent cures all.</span><o:p></o:p></span></div>
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<span style="font-family: Georgia, Times New Roman, serif;"><br /></span></div>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Revision>0</o:Revision>
  <o:TotalTime>0</o:TotalTime>
  <o:Pages>1</o:Pages>
  <o:Words>1944</o:Words>
  <o:Characters>11083</o:Characters>
  <o:Company>CSIR Hqrs</o:Company>
  <o:Lines>92</o:Lines>
  <o:Paragraphs>26</o:Paragraphs>
  <o:CharactersWithSpaces>13001</o:CharactersWithSpaces>
  <o:Version>14.0</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->

<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:View>Normal</w:View>
  <w:Zoom>0</w:Zoom>
  <w:TrackMoves/>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>JA</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
   <w:UseFELayout/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="276">
  <w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>
  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" Priority="59" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->

<!--[if gte mso 10]>
<style>
 /* Style Definitions */
table.MsoNormalTable
 {mso-style-name:"Table Normal";
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-parent:"";
 mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
 mso-para-margin:0cm;
 mso-para-margin-bottom:.0001pt;
 mso-pagination:widow-orphan;
 font-size:12.0pt;
 font-family:Cambria;
 mso-ascii-font-family:Cambria;
 mso-ascii-theme-font:minor-latin;
 mso-hansi-font-family:Cambria;
 mso-hansi-theme-font:minor-latin;}
</style>
<![endif]-->



<!--StartFragment-->









































































































































<!--EndFragment--><br />
<div class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph;">
<br /></div>
</div>
<div style='clear: both;'></div>
</div>
<div class='post-footer'>
<div class='post-footer-line post-footer-line-1'>
<span class='post-author vcard'>
Posted by
<span class='fn' itemprop='author' itemscope='itemscope' itemtype='http://schema.org/Person'>
<meta content='https://www.blogger.com/profile/12006645854589278188' itemprop='url'/>
<a class='g-profile' href='https://www.blogger.com/profile/12006645854589278188' rel='author' title='author profile'>
<span itemprop='name'>Zakir Thomas</span>
</a>
</span>
</span>
<span class='post-timestamp'>
at
<meta content='http://innovip.blogspot.com/2014/08/the-limits-of-patent-system.html' itemprop='url'/>
<a class='timestamp-link' href='http://innovip.blogspot.com/2014/08/the-limits-of-patent-system.html' rel='bookmark' title='permanent link'><abbr class='published' itemprop='datePublished' title='2014-08-13T09:34:00-07:00'>9:34 AM</abbr></a>
</span>
<span class='reaction-buttons'>
</span>
<span class='post-comment-link'>
<a class='comment-link' href='http://innovip.blogspot.com/2014/08/the-limits-of-patent-system.html#comment-form' onclick=''>
No comments:
    </a>
</span>
<span class='post-backlinks post-comment-link'>
</span>
<span class='post-icons'>
<span class='item-control blog-admin pid-946377361'>
<a href='https://www.blogger.com/post-edit.g?blogID=4174420951068114981&postID=8447122701918047778&from=pencil' title='Edit Post'>
<img alt='' class='icon-action' height='18' src='//img2.blogblog.com/img/icon18_edit_allbkg.gif' width='18'/>
</a>
</span>
</span>
<div class='post-share-buttons goog-inline-block'>
<a class='goog-inline-block share-button sb-email' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=8447122701918047778&target=email' target='_blank' title='Email This'><span class='share-button-link-text'>Email This</span></a><a class='goog-inline-block share-button sb-blog' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=8447122701918047778&target=blog' onclick='window.open(this.href, "_blank", "height=270,width=475"); return false;' target='_blank' title='BlogThis!'><span class='share-button-link-text'>BlogThis!</span></a><a class='goog-inline-block share-button sb-twitter' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=8447122701918047778&target=twitter' target='_blank' title='Share to Twitter'><span class='share-button-link-text'>Share to Twitter</span></a><a class='goog-inline-block share-button sb-facebook' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=8447122701918047778&target=facebook' onclick='window.open(this.href, "_blank", "height=430,width=640"); return false;' target='_blank' title='Share to Facebook'><span class='share-button-link-text'>Share to Facebook</span></a><a class='goog-inline-block share-button sb-pinterest' href='https://www.blogger.com/share-post.g?blogID=4174420951068114981&postID=8447122701918047778&target=pinterest' target='_blank' title='Share to Pinterest'><span class='share-button-link-text'>Share to Pinterest</span></a><div class='goog-inline-block google-plus-share-container'><g:plusone source='blogger:blog:plusone' href='http://innovip.blogspot.com/2014/08/the-limits-of-patent-system.html' size='medium' width='300' annotation='inline'/></div>
</div>
</div>
<div class='post-footer-line post-footer-line-2'>
<span class='post-labels'>
</span>
</div>
<div class='post-footer-line post-footer-line-3'>
<span class='post-location'>
</span>
</div>
</div>
</div>
</div>

        </div></div>
      
</div>
<div class='blog-pager' id='blog-pager'>
<span id='blog-pager-older-link'>
<a class='blog-pager-older-link' href='http://innovip.blogspot.com/search?updated-max=2014-08-13T09:34:00-07:00&amp;max-results=7' id='Blog1_blog-pager-older-link' title='Older Posts'>Older Posts</a>
</span>
<a class='home-link' href='http://innovip.blogspot.com/'>Home</a>
</div>
<div class='clear'></div>
<div class='blog-feeds'>
<div class='feed-links'>
Subscribe to:
<a class='feed-link' href='http://innovip.blogspot.com/feeds/posts/default' target='_blank' type='application/atom+xml'>Posts (Atom)</a>
</div>
</div>
<script type="text/javascript">window.___gcfg = {'lang': 'en'};</script>
</div></div>
</div>
</div>
<div class='column-left-outer'>
<div class='column-left-inner'>
<aside>
</aside>
</div>
</div>
<div class='column-right-outer'>
<div class='column-right-inner'>
<aside>
<div class='sidebar section' id='sidebar-right-1'><div class='widget BlogArchive' id='BlogArchive1'>
<h2>Blog Archive</h2>
<div class='widget-content'>
<div id='ArchiveList'>
<div id='BlogArchive1_ArchiveList'>
<ul class='hierarchy'>
<li class='archivedate expanded'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy toggle-open'>

        &#9660;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/search?updated-min=2015-01-01T00:00:00-08:00&amp;updated-max=2016-01-01T00:00:00-08:00&amp;max-results=4'>
2015
</a>
<span class='post-count' dir='ltr'>(4)</span>
<ul class='hierarchy'>
<li class='archivedate expanded'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy toggle-open'>

        &#9660;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2015_08_01_archive.html'>
August
</a>
<span class='post-count' dir='ltr'>(3)</span>
<ul class='posts'>
<li><a href='http://innovip.blogspot.com/2015/08/why-are-r-centers-closing-down.html'>Why are Indian R&amp;D Centers Closing Down?</a></li>
<li><a href='http://innovip.blogspot.com/2015/08/the-economist-decries-patent-system.html'>The Economist Decries Patent System</a></li>
<li><a href='http://innovip.blogspot.com/2015/08/the-curious-copyright-case-of-happy.html'>The Curious Copyright Case of Happy Birthday Song</a></li>
</ul>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2015_01_01_archive.html'>
January
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/search?updated-min=2014-01-01T00:00:00-08:00&amp;updated-max=2015-01-01T00:00:00-08:00&amp;max-results=7'>
2014
</a>
<span class='post-count' dir='ltr'>(7)</span>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2014_08_01_archive.html'>
August
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2014_07_01_archive.html'>
July
</a>
<span class='post-count' dir='ltr'>(2)</span>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2014_05_01_archive.html'>
May
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2014_04_01_archive.html'>
April
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2014_03_01_archive.html'>
March
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2014_02_01_archive.html'>
February
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/search?updated-min=2013-01-01T00:00:00-08:00&amp;updated-max=2014-01-01T00:00:00-08:00&amp;max-results=6'>
2013
</a>
<span class='post-count' dir='ltr'>(6)</span>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2013_09_01_archive.html'>
September
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2013_07_01_archive.html'>
July
</a>
<span class='post-count' dir='ltr'>(1)</span>
</li>
</ul>
<ul class='hierarchy'>
<li class='archivedate collapsed'>
<a class='toggle' href='javascript:void(0)'>
<span class='zippy'>

        &#9658;&#160;
      
</span>
</a>
<a class='post-count-link' href='http://innovip.blogspot.com/2013_06_01_archive.html'>
June
</a>
<span class='post-count' dir='ltr'>(4)</span>
</li>
</ul>
</li>
</ul>
</div>
</div>
<div class='clear'></div>
<span class='widget-item-control'>
<span class='item-control blog-admin'>
<a class='quickedit' href='//www.blogger.com/rearrange?blogID=4174420951068114981&widgetType=BlogArchive&widgetId=BlogArchive1&action=editWidget&sectionId=sidebar-right-1' onclick='return _WidgetManager._PopupConfig(document.getElementById("BlogArchive1"));' target='configBlogArchive1' title='Edit'>
<img alt='' height='18' src='//img1.blogblog.com/img/icon18_wrench_allbkg.png' width='18'/>
</a>
</span>
</span>
<div class='clear'></div>
</div>
</div></div>
<table border='0' cellpadding='0' cellspacing='0' class='section-columns columns-2'>
<tbody>
<tr>
<td class='first columns-cell'>
<div class='sidebar section' id='sidebar-right-2-1'><div class='widget Profile' id='Profile1'>
<h2>About Me</h2>
<div class='widget-content'>
<a href='https://www.blogger.com/profile/12006645854589278188'><img alt='My Photo' class='profile-img' height='80' src='//images-blogger-opensocial.googleusercontent.com/gadgets/proxy?url=http://4.bp.blogspot.com/-5TpdY4mI-hc/U7ogqd2-BDI/AAAAAAAABgg/4ge8dQa0zYc/s113/*&container=blogger&gadget=a&rewriteMime=image/*' width='36'/></a>
<dl class='profile-datablock'>
<dt class='profile-data'>
<a class='profile-name-link g-profile' href='https://www.blogger.com/profile/12006645854589278188' rel='author' style='background-image: url(//www.blogger.com/img/logo-16.png);'>
Zakir Thomas
</a>
</dt>
</dl>
<a class='profile-link' href='https://www.blogger.com/profile/12006645854589278188' rel='author'>View my complete profile</a>
<div class='clear'></div>
<span class='widget-item-control'>
<span class='item-control blog-admin'>
<a class='quickedit' href='//www.blogger.com/rearrange?blogID=4174420951068114981&widgetType=Profile&widgetId=Profile1&action=editWidget&sectionId=sidebar-right-2-1' onclick='return _WidgetManager._PopupConfig(document.getElementById("Profile1"));' target='configProfile1' title='Edit'>
<img alt='' height='18' src='//img1.blogblog.com/img/icon18_wrench_allbkg.png' width='18'/>
</a>
</span>
</span>
<div class='clear'></div>
</div>
</div></div>
</td>
<td class='columns-cell'>
<div class='sidebar section' id='sidebar-right-2-2'></div>
</td>
</tr>
</tbody>
</table>
<div class='sidebar section' id='sidebar-right-3'></div>
</aside>
</div>
</div>
</div>
<div style='clear: both'></div>
<!-- columns -->
</div>
<!-- main -->
</div>
</div>
<div class='main-cap-bottom cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
<footer>
<div class='footer-outer'>
<div class='footer-cap-top cap-top'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
<div class='fauxborder-left footer-fauxborder-left'>
<div class='fauxborder-right footer-fauxborder-right'></div>
<div class='region-inner footer-inner'>
<div class='foot section' id='footer-1'></div>
<table border='0' cellpadding='0' cellspacing='0' class='section-columns columns-2'>
<tbody>
<tr>
<td class='first columns-cell'>
<div class='foot section' id='footer-2-1'></div>
</td>
<td class='columns-cell'>
<div class='foot section' id='footer-2-2'></div>
</td>
</tr>
</tbody>
</table>
<!-- outside of the include in order to lock Attribution widget -->
<div class='foot section' id='footer-3' name='Footer'><div class='widget Attribution' id='Attribution1'>
<div class='widget-content' style='text-align: center;'>
Simple template. Powered by <a href='https://www.blogger.com' target='_blank'>Blogger</a>.
</div>
<div class='clear'></div>
<span class='widget-item-control'>
<span class='item-control blog-admin'>
<a class='quickedit' href='//www.blogger.com/rearrange?blogID=4174420951068114981&widgetType=Attribution&widgetId=Attribution1&action=editWidget&sectionId=footer-3' onclick='return _WidgetManager._PopupConfig(document.getElementById("Attribution1"));' target='configAttribution1' title='Edit'>
<img alt='' height='18' src='//img1.blogblog.com/img/icon18_wrench_allbkg.png' width='18'/>
</a>
</span>
</span>
<div class='clear'></div>
</div></div>
</div>
</div>
<div class='footer-cap-bottom cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
</footer>
<!-- content -->
</div>
</div>
<div class='content-cap-bottom cap-bottom'>
<div class='cap-left'></div>
<div class='cap-right'></div>
</div>
</div>
</div>
<script type='text/javascript'>
    window.setTimeout(function() {
        document.body.className = document.body.className.replace('loading', '');
      }, 10);
  </script>
<script type="text/javascript">
if (window.jstiming) window.jstiming.load.tick('widgetJsBefore');
</script><script type="text/javascript" src="https://www.blogger.com/static/v1/widgets/278981662-widgets.js"></script>
<script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script>
<script type='text/javascript'>
if (typeof(BLOG_attachCsiOnload) != 'undefined' && BLOG_attachCsiOnload != null) { window['blogger_templates_experiment_id'] = "templatesV2";window['blogger_blog_id'] = '4174420951068114981';BLOG_attachCsiOnload(''); }_WidgetManager._Init('//www.blogger.com/rearrange?blogID\x3d4174420951068114981','//innovip.blogspot.com/','4174420951068114981');
_WidgetManager._SetDataContext([{'name': 'blog', 'data': {'blogId': '4174420951068114981', 'bloggerUrl': 'https://www.blogger.com', 'title': 'Random Thoughts: On R\46amp;D, Innovation, IP and IT', 'pageType': 'index', 'url': 'http://innovip.blogspot.com/', 'canonicalUrl': 'http://innovip.blogspot.com/', 'homepageUrl': 'http://innovip.blogspot.com/', 'canonicalHomepageUrl': 'http://innovip.blogspot.com/', 'blogspotFaviconUrl': 'http://innovip.blogspot.com/favicon.ico', 'enabledCommentProfileImages': true, 'adultContent': false, 'analyticsAccountNumber': '', 'useUniversalAnalytics': false, 'pageName': '', 'pageTitle': 'Random Thoughts: On R\46amp;D, Innovation, IP and IT', 'encoding': 'UTF-8', 'locale': 'en', 'localeUnderscoreDelimited': 'en', 'isPrivate': false, 'isMobile': false, 'isMobileRequest': false, 'mobileClass': '', 'isPrivateBlog': false, 'languageDirection': 'ltr', 'feedLinks': '\74link rel\75\42alternate\42 type\75\42application/atom+xml\42 title\75\42Random Thoughts: On R\46amp;D, Innovation, IP and IT - Atom\42 href\75\42http://innovip.blogspot.com/feeds/posts/default\42 /\76\n\74link rel\75\42alternate\42 type\75\42application/rss+xml\42 title\75\42Random Thoughts: On R\46amp;D, Innovation, IP and IT - RSS\42 href\75\42http://innovip.blogspot.com/feeds/posts/default?alt\75rss\42 /\76\n\74link rel\75\42service.post\42 type\75\42application/atom+xml\42 title\75\42Random Thoughts: On R\46amp;D, Innovation, IP and IT - Atom\42 href\75\42https://www.blogger.com/feeds/4174420951068114981/posts/default\42 /\76\n', 'meTag': '\74link rel\75\42me\42 href\75\42https://www.blogger.com/profile/12006645854589278188\42 /\76\n', 'openIdOpTag': '\74link rel\75\42openid.server\42 href\75\42https://www.blogger.com/openid-server.g\42 /\76\n\74link rel\75\42openid.delegate\42 href\75\42http://innovip.blogspot.com/\42 /\76\n', 'latencyHeadScript': '\74script type\75\42text/javascript\42\76(function() { (function(){function c(a){this.t\75{};this.tick\75function(a,c,b){var d\75void 0!\75b?b:(new Date).getTime();this.t[a]\75[d,c];if(void 0\75\75b)try{window.console.timeStamp(\42CSI/\42+a)}catch(e){}};this.tick(\42start\42,null,a)}var a;window.performance\46\46(a\75window.performance.timing);var h\75a?new c(a.responseStart):new c;window.jstiming\75{Timer:c,load:h};if(a){var b\75a.navigationStart,e\75a.responseStart;0\74b\46\46e\76\75b\46\46(window.jstiming.srt\75e-b)}if(a){var d\75window.jstiming.load;0\74b\46\46e\76\75b\46\46(d.tick(\42_wtsrt\42,void 0,b),d.tick(\42wtsrt_\42,\n\42_wtsrt\42,e),d.tick(\42tbsd_\42,\42wtsrt_\42))}try{a\75null,window.chrome\46\46window.chrome.csi\46\46(a\75Math.floor(window.chrome.csi().pageT),d\46\0460\74b\46\46(d.tick(\42_tbnd\42,void 0,window.chrome.csi().startE),d.tick(\42tbnd_\42,\42_tbnd\42,b))),null\75\75a\46\46window.gtbExternal\46\46(a\75window.gtbExternal.pageT()),null\75\75a\46\46window.external\46\46(a\75window.external.pageT,d\46\0460\74b\46\46(d.tick(\42_tbnd\42,void 0,window.external.startE),d.tick(\42tbnd_\42,\42_tbnd\42,b))),a\46\46(window.jstiming.pt\75a)}catch(k){}})();window.tickAboveFold\75function(c){var a\0750;if(c.offsetParent){do a+\75c.offsetTop;while(c\75c.offsetParent)}c\75a;750\76\75c\46\46window.jstiming.load.tick(\42aft\42)};var f\75!1;function g(){f||(f\75!0,window.jstiming.load.tick(\42firstScrollTime\42))}window.addEventListener?window.addEventListener(\42scroll\42,g,!1):window.attachEvent(\42onscroll\42,g);\n })();\74/script\076', 'mobileHeadScript': '', 'ieCssRetrofitLinks': '\74!--[if IE]\76\74script type\75\42text/javascript\42 src\75\42https://www.blogger.com/static/v1/jsbin/1494333581-ieretrofit.js\42\76\74/script\76\n\74![endif]--\076', 'view': '', 'dynamicViewsCommentsSrc': '//www.blogblog.com/dynamicviews/4224c15c4e7c9321/js/comments.js', 'dynamicViewsScriptSrc': '//www.blogblog.com/dynamicviews/433c1c2e1ace5832', 'plusOneApiSrc': 'https://apis.google.com/js/plusone.js', 'sf': 'n'}}, {'name': 'messages', 'data': {'archive': 'Archive', 'deleteBacklink': 'Delete Backlink', 'deleteComment': 'Delete Comment', 'emailAddress': 'Email Address', 'getEmailNotifications': 'Get email notifications', 'keepReading': 'Keep reading', 'labels': 'Labels', 'loadMorePosts': 'Load more posts', 'loading': 'Loading...', 'myBlogList': 'My Blog List', 'myFavoriteSites': 'My favorite sites', 'newer': 'Newer', 'newerPosts': 'Newer Posts', 'newest': 'Newest', 'noResultsFound': 'No results found', 'noTitle': 'No title', 'older': 'Older', 'olderPosts': 'Older Posts', 'oldest': 'Oldest', 'onlyTeamMembersCanComment': 'Note: Only a member of this blog may post a comment.', 'popularPosts': 'Popular Posts', 'popularPostsFromThisBlog': 'Popular posts from this blog', 'postAComment': 'Post a Comment', 'reportAbuse': 'Report Abuse', 'search': 'Search', 'share': 'Share', 'showAll': 'Show all', 'subscribe': 'Subscribe', 'subscribeToThisBlog': 'Subscribe to this blog', 'theresNothingHere': 'There\47s nothing here!'}}, {'name': 'skin', 'data': {'vars': {'post_footer_background_color': '#f9f9f9', 'tabs_text_color': '#ffffff', 'date_header_letterspacing': 'inherit', 'content_shadow_spread': '40px', 'body_background_override': '', 'description_text_size': '140%', 'mobile_background_size': 'auto', 'header_shadow_spread': '1px', 'image_border_color': '#eeeeee', 'date_header_color': '#222222', 'header_shadow_offset_top': '-1px', 'header_border_horizontalsize': '0', 'widget_title_font': 'normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif', 'tabs_border_color': '#eeeeee', 'tabs_bevel_border_width': '1px', 'body_background_gradient_tile': 'url(//www.blogblog.com/1kt/simple/body_gradient_tile_light.png)', 'description_text_color': '#222222', 'main_section_margin': '15px', 'post_title_font': 'normal bold 30px Copse', 'page_width': 'auto', 'paging_background': 'transparent none no-repeat scroll top center', 'body_text_color': '#222222', 'content_padding': '10px', 'header_background_gradient': 'none', 'post_margin_bottom': '25px', 'header_shadow_offset_left': '-1px', 'tabs_background_color': '#ffffff', 'content_background_color': '#ffffff', 'body_background_gradient_cap': 'url(//www.blogblog.com/1kt/simple/gradients_light.png)', 'main_padding_top': '30px', 'widget_alternate_text_color': '#999999', 'image_text_color': '#222222', 'link_visited_color': '#888888', 'tabs_margin_side': '30px', 'image_border_large_size': '5px', 'content_shadow_spread_webkit': '5px', 'mobile_button_color': '#ffffff', 'tabs_selected_text_color': '#000000', 'main_border_width': '0', 'content_background_color_selector': '.content-inner', 'link_color': '#2288bb', 'post_footer_border_color': '#eeeeee', 'date_header_font': 'normal bold 11px Arial, Tahoma, Helvetica, FreeSans, sans-serif', 'tabs_background_gradient': 'url(//www.blogblog.com/1kt/simple/gradients_light.png)', 'content_padding_horizontal': '10px', 'header_font': 'normal bold 42px Reenie Beanie', 'startSide': 'left', 'tabs_font': 'normal normal 14px Arial, Tahoma, Helvetica, FreeSans, sans-serif', 'widget_title_text_color': '#000000', 'header_border_size': '1px', 'tabs_selected_background_color': '#eeeeee', 'date_header_margin': 'inherit', 'footer_bevel': '0', 'image_border_small_size': '2px', 'content_shadow_spread_ie': '10px', 'mobile_background_overlay': 'transparent none repeat scroll top left', 'endSide': 'right', 'date_header_padding': 'inherit', 'image_background_color': '#ffffff', 'body_rule_color': '#eeeeee', 'header_bottom_border_size': '1px', 'page_width_selector': '.region-inner', 'body_background_color': '#66bbdd', 'header_text_color': '#5690c3', 'main_padding': '15px', 'date_header_background_color': 'transparent', 'tabs_border_width': '1px', 'body_font': 'normal normal 12px Arial, Tahoma, Helvetica, FreeSans, sans-serif', 'link_hover_color': '#33aaff', 'header_background_color': 'transparent', 'keycolor': '#66bbdd', 'main_padding_bottom': '30px', 'post_footer_text_color': '#666666', 'tabs_margin_top': '0', 'header_padding': '30px'}, 'override': ''}}, {'name': 'view', 'data': {'classic': {'name': 'classic', 'url': '?view\75classic'}, 'flipcard': {'name': 'flipcard', 'url': '?view\75flipcard'}, 'magazine': {'name': 'magazine', 'url': '?view\75magazine'}, 'mosaic': {'name': 'mosaic', 'url': '?view\75mosaic'}, 'sidebar': {'name': 'sidebar', 'url': '?view\75sidebar'}, 'snapshot': {'name': 'snapshot', 'url': '?view\75snapshot'}, 'timeslide': {'name': 'timeslide', 'url': '?view\75timeslide'}}}]);
_WidgetManager._RegisterWidget('_NavbarView', new _WidgetInfo('Navbar1', 'navbar', null, document.getElementById('Navbar1'), {}, 'displayModeFull'));
_WidgetManager._RegisterWidget('_HeaderView', new _WidgetInfo('Header1', 'header', null, document.getElementById('Header1'), {}, 'displayModeFull'));
_WidgetManager._RegisterWidget('_BlogView', new _WidgetInfo('Blog1', 'main', null, document.getElementById('Blog1'), {'cmtInteractionsEnabled': false, 'lightboxEnabled': true, 'lightboxModuleUrl': 'https://www.blogger.com/static/v1/jsbin/4156661259-lbx.js', 'lightboxCssUrl': 'https://www.blogger.com/static/v1/v-css/1185134592-lightbox_bundle.css'}, 'displayModeFull'));
_WidgetManager._RegisterWidget('_BlogArchiveView', new _WidgetInfo('BlogArchive1', 'sidebar-right-1', null, document.getElementById('BlogArchive1'), {'languageDirection': 'ltr', 'loadingMessage': 'Loading...'}, 'displayModeFull'));
_WidgetManager._RegisterWidget('_ProfileView', new _WidgetInfo('Profile1', 'sidebar-right-2-1', null, document.getElementById('Profile1'), {}, 'displayModeFull'));
_WidgetManager._RegisterWidget('_AttributionView', new _WidgetInfo('Attribution1', 'footer-3', null, document.getElementById('Attribution1'), {'attribution': 'Simple template. Powered by \74a href\75\47https://www.blogger.com\47 target\75\47_blank\47\76Blogger\74/a\76.'}, 'displayModeFull'));
</script>
</body>
</html>